

CLINAM

9/2016
Basel, June 26-29

Conference and Exhibition

European & Global Summit for Cutting-Edge Medicine

June 26 – 29, 2016

Clinical Nanomedicine and Targeted Medicine

Enabling Technologies for Personalized Medicine

FINAL PROGRAMME (19.6.16)

Registration Desk at Center: Sunday 16.00 – 18.00; Monday, Tuesday 07.30 – 18.00; Wednesday 07.30 – 16.00

In Collaboration with:



Conference Venue:

Congress Center, Messeplatz 21, 4058 Basel, Switzerland Phone +41 58 206 28 28, info@congress.ch

Organizers Office:

European Foundation for Clinical Nanomedicine (CLINAM) Alemannengasse 12, P.B. 4016 Basel, Switzerland
Phone +41 61 695 93 95 clinam@clinam.org

Registration Office:

Organizers Schweiz GmbH, CLINAM SUMMIT 9/2016 Obere Egg 2, CH 4312 Magden, Switzerland
Phone +41 61 836 98 78 registration@organizers.ch

Congress Center  Basel

Congress Center Basel, Messeplatz 21, 2058 Basel 2nd Floor, Switzerland, Phone +41 58 206 28

SUN 26.6.	NanoAthero Event for young Researchers 14.30 – 17.00 <i>Prof. Dr. Didier Letourneur</i> , Project Coordinator NanoAthero				ALL MEETINGS AT HALL OSAKA & SAMARKAND
15.30	General Assembly of the European Society for Nanomedicine				
16.45	General Assembly of the International Society for Nanomedicine				
18.00	Editorial Board Meeting, European Journal of Nanomedicine				
19.45 WELCOME DINNER FOR SPEAKERS AND INVITED GUESTS AT SWISSÔTEL LE PLAZA, DINING ROOM HELVETIA, FIRST FLOOR					
MON 27.6.	HALL MONTREAL PLENARY	HALL SYDNEY SESSIONS	HALL SINGAPORE SESSIONS	HALL RIO SESSIONS	OSAKA/SAMARKAND SATELLITES
08.00 WELCOME COFFEE					
08.30	1 Opening CLINAM, EU, BASEL, University, Switzerland				
09.30	2 Scientific Introduction CLINAM 9 /2016: <i>Prof Dr. med Patrick Hunziker</i>				
09.45 BREAK					
10.20	3 Opening Keynote: <i>Prof. Dr. Stefan Hell</i> , Nobel Laureate, "Optical Microscopy: the Resolution Revolution"				
11.15	4 Unsolved Problems and Clinical Challenges in Medicine: Eye Disease; Cancer, Infection				
11.55	5 Keynote: <i>Prof. Dr. med. Carl June</i> "Engineering T Cells for Cancer Therapy: Chances and Opportunities"				
12.45 LUNCH					
13.45	6 Theranostics	7 Immuno-Oncology	8 Strategies Targeting	9 Small Speeches of Posters and University Village	10 Biomedical Sensing and Analytics
16.30 BREAK					
17.00	11 Keynotes: Pushing the Limits of Nanomedicine <i>Dr. Patri, Prof. Dr. Gerber, Prof. Dr. Ben-Sasson</i>				
19.00 END OF DAY 1 19.35 WE MEET IN FRONT OF SWISSÔTEL LE PLAZA 19.45 LEAVING BY RENTED TRAMWAY (LINE 6) 20.00 DINNER					
TUE 28.6.	HALL MONTREAL PLENARY	HALL SYDNEY SESSIONS	HALL SINGAPORE SESSIONS	HALL RIO SESSIONS	OSAKA/SAMARKAND SATELLITES
08.15	12 Pediatric Nanomedicine	13 Computational Modelling in Nanomedicine	14 Nanomedicines: In Vitro- in Vivo-Correlations	15 The Big Picture of Nanomedicine	
09.30 BREAK					
10.00	16 Pharmaceutical Development of Nano-medicine Medications	17 Gene Editing for Nanomedical Approaches	18 Nanomedicine for Ophthalmic Disease and Otorhinolaryngology 19 Graphene in NM & Nanotox	20 Assessing Complex Drug Similarity (NBCDs)	
11.50 CHANGE FOR PLENARY SESSION					
12.00	21 Advanced Image Analysis, <i>Prof. Dr. Gerd Binnig</i> ; Nobel Laureate				
12.40 LUNCH					22 CLOSED Meeting Regulatory Authorities, Separate Lunch Room Miami
13.40	23 Cancer Nanomedicine in Diagnostica and Therapy	24 Immunogenicity, Toxicity and Safety of Nanoparticles	25 Rare and Neglected Diseases	26 Nanodrug Delivery: Novel Insights and Strategies	27 Advanced Dendrimer based Results in Medicine
16.00 BREAK					
16.30	28 The Regulatory Authorities' Voice 2016 (16.30 – 18.00)				
18.30	29 Awarding the poster prizez for the best 3 Posters in 3 categories & Apéritif				
19.15 END OF DAY 2 19.45 SPEAKERS AND INVITED GUESTS MEET IN FRONT OF SWISSÔTEL LE PLAZA 20.00 SPEAKERS DINNER AT TERRASSES OF HOTEL MERIAN SPITZ					
WED 29.6.	HALL MONTREAL PLENARY	HALL SYDNEY SESSIONS	HALL SINGAPORE SESSIONS	HALL RIO SESSIONS	HALL LIMA (GROUND FLOOR) SATELLITES
08.15	30 Late Breaking and Ongoing Trials 1	31 Nanomedical Approaches in Infection and Inflammation	32 Materials Science in Nanomedicine	33 Nanomedical Applications for Diagnostics and Therapy	
09.45 BREAK					
10.15	34 Late Breaking and Ongoing Trials 2	35 Cardiology in Atherosclerosis	36 Novel insights into Basic Mechanisms of Cancer	37 The European Nano-medicine Characterization Lab infrastructure	38 Ethics in Nanomedicine
11.40 CHANGE TO PLENARY SESSION					
11.50	39 Keynote: <i>Prof. Dr. Erem Bilensoy</i> , Clinical Outcome and Regulatory Approaches for Nanomedicine and Advanced Delivery Products				
12.30 LUNCH					
13.30	40 Bio-Corona and its relevance for Nano-medicine and Delivery	41 Tissue Engineering for Drug Development	42 Nanomedicine in Brain Disease	43 Medical Applications for Nanomedicine in Oncology	44 Education and Workforce Training in Nanomedicine
14.45 SHORT BREAK AND CHANGE TO PLENARY SESSION HALL MONTREAL					
15.00	45 Two Keynote Sessions: <i>Prof. Dr. med. Omid Farokhzad</i> – Tumor Microenvironment Variability – New Nanoparticle Design and Patient Selection <i>Prof. Dr. Jérôme Galon</i> : Redefining Cancer by Integrating the Immune System: Transferring Cutting Edge Medicine to the Patients				
16.20	46 The Spur on Nanomedicine – Voices from the participants of CLINAM 9/16 with <i>Prof. Dr. Chezy Barenholz</i>				
16.50	Closing Words on the CLINAM 9/2016 Debate Conference, <i>Prof. Dr. med. Patrick Hunziker</i> , President of the International Society for Nanomedicine, Basel (CH)				
17.00 END OF CLINAM 9/2016 18.30 LIGHT FAREWELL DINNER FOR STAYING SPEAKERS AND INVITED GUESTS					

Contents of the Programme Folder

Collaborators, Sponsors and Scientific Committee	3
Introduction – Summit at a Glance	4
Final Programme	4
Sunday and Monday	4
Tuesday	10
Wednesday	19
Organizers Office & Registration Office	27
Copyright and Liability by CLINAM	27
Option to Live Test your Sample on STED Microscope	27
The Exhibitors	28
University Village and Small Speeches	28
Late Submission of Posters (not in Proceedings)	29
Installation of Posters, Size and Presentation Times	29
Special Event “NanoAthero” in Sunday, June 26, 2016	30
Facilitators of the European CLINAM-Summit 2016	30
Registration Fees for Conference and Exhibition	30
How to get to Basel Congress Center	31
Sponsors of the CLINAM Summit 2016	32

The Collaborators of the European and Global CLINAM-Summit 2016

• **Federal** Department of Economic Affairs, Education and Research of the Swiss Confederation, Bern (CH)
 • **Association** for Cancer Immunotherapy (CIMT). Mainz (D) • **BioNanoNet** Forschungs-GmbH, Graz (A) • **Cantons** of Basel (CH) • **Chinese** Academy of Sciences, Beijing (RC) • **De Gruyter** – European Journal of Nanomedicine, Berlin (D)
 • **DIA** Europe, Middle East & Africa, Basel (CH) • **EMPA**, Swiss Federal Laboratories for Materials Science, Dübendorf (CH) • **European** Academy of Sciences and Arts, Salzburg (A) • **European** Commission, Brussels (B) • **European** Forum for Good Clinical Practice EFGCP, Brussels (B) • **European** Materials Research Society, Strasbourg (F) • **European** Medicines Agency (EMA), London (UK) • **European** Society for Nanomedicine, Basel (CH) • **European** Technology Platform of Nanomedicine (ETPN) • Euro Nanotox Letters (A) • **Freiwillige** Akademische Gesellschaft (FAG, Basel) (CH) • **Food** and Drug Administration, (FDA) Silver Spring (USA) • **Helmholtz** Institute for Pharmaceutical Research Saarland (HIPS), Saarbrücken (D) • **Innovative** Medicines Initiative, (IMI) Brussels • **International** Association for Pharmaceutical Technology (APV), Mainz (D) • **Key Laboratory** for Biomedical Effects of Nanomaterials and Nanosafety, Beijing (RC) • **Lundbeckfonden** Center of Excellence NanoCAN, Odense (DK) • **Nanomedicines** Alliances, Research Triangle Park (USA) • **National** Institute of Health Sciences of Japan, Tokyo (J) • **National** Center for Nanoscience and Technology of China, Beijing (RC) • **Non Biological** Complex Drugs Working Group, (NBCD) Leiden(NL) • **Nanotech Characterization Laboratory**, National Cancer Institute, Frederick (USA) • **Swiss Biotech** Association, Zürich (CH) • **University** of Basel, Basel (CH)

The Sponsors of the European and Global CLINAM-Summit 2016

• Federal Department of Economic Affairs, Education and Research of the Swiss Confederation, Bern (CH)
 • Actelion Pharmaceuticals Ltd. Allschwil (CH) • Freiwillige Akademische Gesellschaft Basel, • The Canton of Basel-Stadt(CH) • The Canton of Basel-Land (CH) • Clariant International AG, Pratteln (CH) • Isaac Dreyfus Bernheim Foundation, Basel (CH) • European Materials Forum, Brussels (B) • European Materials Research Society (E-MRS), Strasbourg (F) • GAG AG, Basel (CH) • Löffler & Associates GmbH - Concept Engineering, Basel (CH) • Lonza Ltd., Basel (CH) • Novartis (CH) • Roche (CH) • Swiss NanoScience Institute, Basel • Swiss National Science Foundation, Bern (CH) • Tarveda Therapeutics, Watertown, MA (USA) • TecoMedical Group, Sissach (CH) • University of Basel (CH)

Scientific Committee

• **Prof. Dr. med. Patrick Hunziker**, University Hospital Basel (CH) (chairman) • **Prof. Dr. med. Christoph Alexiou**, University Hospital Erlangen (D) • **Prof. Dr. Lajos Balogh**, AA Nanomedicine and Nanotechnology Consultants, North Andover, Massachusetts, American Society for Nanomedicine, Boston (USA) • **Prof. Dr. Yechezkel Barenholz**, Hebrew University, Hadassah Medical School, Jerusalem (IL) • **Prof. Dr. Gerd Binnig**, Nobel Laureate, Munich (D) • **Prof. Dr. med. Omid Farokhzad**, Associate Professor and Director of Laboratory of Nanomedicine and Biomaterials, Harvard Medical School and Brigham and Women's Hospital, (USA) • **Prof. Dr. med. Dong Soo Lee, PhD.** Chairman Department of Nuclear Medicine Seoul National University Seoul (KOR) • **Dr. med. h.c. Beat Löffler, MA** CLINAM-Foundation, Basel (CH) • **Prof. Dr. Jan Mollenhauer**, Lundbeckfonden Center of Excellence NanoCAN, Odense (DK) • **Prof. Dr. med. Marisa Papaluca Amati**, European Medicines Agency, London (UK) • **Prof. Dr. Gert Storm**, Institute for Pharmaceutical Sciences, Utrecht University, (NL) • **Prof. Dr. Viola Vogel**, Laboratory for Biologically Oriented Materials, ETH, Zürich (CH)

Introduction – The Conference at a Glance

In the previous eight years, the CLINAM Summit grew to the largest in its field with 12 presenting Noble Laureates and more than 500 participants from academia, industry, regulatory authorities and policy from over 40 countries in Europe and worldwide. With this success and broad support by well 31 renowned collaborating initiatives, the CLINAM-Summit is today a most important marketplace for scientific exchange and discussions of clinical, regulatory, political and ethical aspects in this field of cutting-edge medicine. The CLINAM Summit emerged as exquisite forum for translation from bench to bedside for European and international networking, for industrial collaboration between companies, with academia, and as point-of-contact with customers. The summit is presently the only place to meet every year the regulatory authorities from all continents to debate the needs of all stakeholders in the field.

CLINAM 9/2016 continues with its tradition to cover the manifold interdisciplinary fields of Clinical and Targeted Nanomedicine in major and neglected diseases. As special focus area, **CLINAM 09/2016 adds translation and enabling technologies, including, cutting-edge molecular profiling, nano-scale analytics, single cell analysis, stem cell technologies, tissue engineering, in and ex vivo systems as well as in vitro substitute systems for efficacy and toxicity testing.** **CLINAM 09/2016** covers the spectrum of Nanomedicine and Targeted Medicine from new materials and enabling technologies over diagnostic and therapeutic translation to clinical applications in infectious, inflammatory and neurodegenerative diseases, cancer and regenerative medicine to societal implications, strategical issues, and regulatory affairs. The Summit is divided into four tracks in parallel and provides ample possibilities for exhibitors to make decision maker contacts. **The Nobel Laureate Prof. Stefan Hell will open the Summit. Participants are invited to bring samples to test the Stimulated Emission Depletion (STED) Microscopy within the exhibition.** For labelling consult at the CLINAM website <https://www.clinam.org/images/pdf/labeling.pdf>.

Final Programme

Sunday, June 26, 2016 (all events on 2nd Floor Halls Osaka and Samarkand)

- 14.30 **NanoAthero** Lecture and Debate on Atherosclerosis with young scientists (until 17.00)
- 15.30 General Assembly of the European Society for Nanomedicine
- 16.45 General Assembly of the International Society for Nanomedicine
- 18.00 Editorial Board Meeting, European Journal of Nanomedicine
- 19.45 Welcome Dinner for Speakers & invited Guests (Swissôtel Le Plaza*****, 1st Floor)**

Monday, June 27, 2016

Section 1: Plenary Session

Monday, Hall Montreal

- Plenary **1. Opening**
- 08.30 **Opening Address from the European Foundation for Clinical Nanomedicine**
Dr. med. h.c. Beat Löffler, CEO, European Foundation for Clinical Nanomedicine, Basel (CH)
- 08.40 **Opening Address from the European Commission**
Dr. Elke Anklam, Director, European Commission, DG Joint Research Centre, Institute for Reference Materials and Measurements, Geel (B)
- 08.50 **Opening Address from the Kanton of Basel-Stadt**
Dr. Lukas Engelberger, Member of the Executive Council of the Canton of Basel-Stadt, Basel (CH)
- 09.00 **Opening Address on behalf of the University of Basel**
Prof. Dr. Andrea Schenker-Wicki, Rector of the University of Basel, Basel (CH)
- 09.10 **Opening Address from Switzerland**
Dr. Gregor Haefliger, Vice Director, Head of National Research and Innovation Division, State Secretariat for Education, Research and Innovation SERI, Bern (CH)

- Monday, Hall Montreal
- Plenary
Chair **2. Scientific Introduction to CLINAM 9 / 2016**
Prof. Dr. med. Christoph Alexiou, Assistant Medical Director, Else Kröner-Fresenius-Foundation Professorship, Head Division Experimental Oncology and Nanomedicine, ENT-Clinic, University Clinic, Erlangen (D)
- 09.30 **The Principles of Translation in Nanomedicine for Personalized Medicine**
Prof. Dr. med. Patrick Hunziker, President of the International Society for Nanomedicine, Basel (CH)
- 09.45 **Break**
- Plenary
Chair Monday, Hall Montreal
3. The Marriage between High-resolution and Live Imaging
Prof. Dr. Christian Schönenberger, Department of Physics, Director of the Swiss Nanoscience Institute, University of Basel, (CH)
- 10.20 Opening Keynote Lecture
Optical Microscopy: The Resolution Revolution
Prof. Dr. Dr. h.c. mult. Stefan W. Hell, Nobel Laureate, Max Planck Institute for Biophysical Chemistry Department of NanoBiophotonics, Göttingen (D)
- 10.55 **Questions and Debate**
- Monday, Hall Montreal
- Plenary
Chair **4. Unsolved Problems and Clinical Challenges in Medicine**
Prof. Dr. med. Christoph Alexiou, Ass. Medical Director, Else Kröner-Fresenius-Foundation Professorship, Head Division Experimental Oncology and Nanomedicine, ENT-Clinic, University Clinic, Erlangen (D)
- 11.15 **Unsolved Fields in Eye Disease**
Prof. Dr. med. Herbert A. Reitsamer, PhD, Vice President Austrian Ophthalmological Society, Director Experimental Ophthalmology, Director Glaucoma Service & Glaucoma Prevention Program SALK/Paracelsus Medical University Salzburg (A)
- 11.25 **Unsolved Problems in Cancer and Future Aspects**
Prof. Dr. med. Volker Mailänder, Leader of the joint research group between the University Dermatology Department, Center for Translational Nanomedicine - CTN, Johannes-Gutenberg University Mainz and the Max Planck Institute (MPI) for Polymer Science, Mainz (D)
- 11.35 **Unsolved Problems in Fungal Infections**
Prof Dr. med. Cornelia Lass-Flörl, Division of Hygiene and Medical Microbiology, Innsbruck Medical University, Innsbruck (A)
- 11.45 **Questions & Debate**
- Monday, Hall Montreal
- Plenary
Chair **5. The Cellular Immune System: Therapies for Cancer and Chronic Infection**
Prof. Dr. Yechezkel (Chezy) Barenholz, Head of Membrane and Liposome Research Lab, Hebrew University Hadassah Medical School, Jerusalem (IL)
- Keynote lecture
- 11.55 **Engineering T-Cells for Cancer Therapy: Challenges and Opportunities**
Prof. Dr. med. Carl June, MD, Richard W Vague Professor in Immunotherapy, Department of Pathology and Laboratory Medicine, Director Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia (USA)
- 12.30 **Questions and Debate**
- 12.45 **Lunch**

Section 2: 4 Parallel Sessions

- Monday, Hall Montreal
- Parallel 1
Chair
- 6. Theranostics – Application of Nanoparticles** (12 min & 3 min Questions)
Prof. Dr. Dr. Twan Lammers, Experimental Molecular Imaging, RWTH Aachen, Aachen (D) and Department of Targeted Therapeutics, University of Twente, Enschede (NL)
- 13.45 **Theranostics: from Targeting and Imaging to Tissue Engineering**
Prof. Dr. Dr. Twan Lammers, Experimental Molecular Imaging, RWTH Aachen, Aachen (D) and Department of Targeted Therapeutics, University of Twente, Enschede (NL)
- 14.00 **Microbubbles for Drug Delivery to Tumors and the Brain**
Prof. Dr. med. Fabian Kiessling, University Hospital Aachen, Director of the Department for Experimental Molecular Imaging (ExMI) RWTH Aachen University, Director of the Helmholtz Institute for Biomedical Engineering, Aachen (D)
- 14.15 **Theranostics Nanomedicine in Cancer and Atherosclerosis**
Prof. Dr. Willem Mulder, Associate Professor of Radiology at Icahn School of Medicine at Mount Sinai, NY, (USA)
- 14.30 **Multimodal Imaging of CNT-mediated Brain Delivery**
Dr. Khuloud T. Al-Jamal, Reader in Nanomedicine, Drug Delivery Group, Institute of Pharmaceutical Science, King's College London, London (UK)
- 14.45 **Inorganic Nanomaterials for Image-guided Surgery**
Dr. med. Moritz F. Kircher, PhD Head of the Moritz Kircher Lab, Memorial Sloan Kettering Cancer Center, New York (USA)
- 15.00 **Translational Optical Molecular Imaging: from Experimental to Clinical Phase III Evaluation in Oncology**
Prof. Dr. Gooitzen M. van Dam, MD, PhD, Professor of Surgical Oncology, Founding Member European Society of Molecular Imaging, WMIS Image-Guided Surgery Working Group, ESMI Fluorescence-Guided Surgery Group, University Medical Center Groningen (NL)
- 15.15 **The Regulatory Authorities View in Theranostics**
Dr. Frank Weichold U.S. Food and Drug Administration, Washington, Washington, D.C. (USA)
- 15.30 **The Pharma Industry Approach in Theranostics**
Dr. Martin Rausch, Director Analytical Sciences & Imaging, Novartis Institute for Biomedical Research (NIBR), Basel (CH)
- 15.45 **Albumin as Natural Nanoparticles for in Vivo Imaging and Drug Delivery**
Prof. Dr. med. Keon W. Kang, MD, PhD Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul (KR)
- 16.00 **Magnetic Particle Imaging – an Innovative Imaging Technique Using Superparamagnetic Iron Oxide Nanoparticles (SPION) – Novel Aspects**
Prof. Dr. med. Christoph Alexiou, Ass. Medical Director, Else Kröner-Fresenius-Foundation Professorship, Head Division Experimental Oncology and Nanomedicine, ENT-Clinic, University Clinic, Erlangen (D)
- 16.15 **Ultrasound Triggered, Image Guided Drug Delivery**
Prof. Dr. Chrit Moonen, Professor of Image Guided Molecular Interventions, Image Sciences Institute, Imaging Division, University Medical Center Utrecht, Utrecht (NL)
- Questions and Debate after each Talk**
- 16.30 **Break**

Monday, Hall Sydney (Session A 13.45 – 15.15)

Parallel 2

7. Immuno-Oncology (15 min & 5 min Questions)

Chair

Prof. Dr. Dan Peer, Head, Laboratory of Nanomedicine, Department of Cell Research & Immunology, and Department of Materials Science & Engineering, Director, FTA: Nanomedicines for Personalized Theranostics, Director, Leona M. and Harry B. Helmsley Nanotechnology Research Fund, Tel Aviv University, Tel-Aviv (IL)

13.45

Bispecific Antibodies for T-Cell Redirection Therapy

Dr. Mark Chiu, Associate Director at Janssen, Pharmaceutical Companies of Johnson and Johnson, Spring House, Pennsylvania (USA)

14.05

Adoptive T-Cell Therapy

Prof. Dr. med. Carl June, MD, Richard W Vague Professor in Immunotherapy, Department of Pathology and Laboratory Medicine, Director Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia (USA)

14.25

Reprogramming the Immune System - Novel Pathways in Pharmaceutical Industry

Dr. Alfonso Quintas-Cardama, Global Clinical Leader, Novartis AG, Basel (CH)

14.45

Cancer Immunotherapy: Strategies for Personalization and Combination Approaches

Prof. Dr. med Alfred Zippelius, Deputy Head of Medical Oncology, University Hospital Basel and Department Biomedicine, Biozentrum, Basel (CH)

15.05

Tissue Derived Neo-antigens for T Cell-based Cancer Immunotherapy

Dr. Michal Bassani-Sternberg, PhD, Director, Immunopeptidomics Unit, Department of Oncology, UNIL/CHUV, Epalinges, (CH)

15.25

Synthetic Peptides for the Activation of Tumor Specific T cells in Selected Likely Responder Patients

Dr. Julianna Lisziewicz, President and Chief Scientific Officer, eMMUNITY, Inc. Budapest (H)

15.45

Questions and Debate

16.30

Break

Monday, Hall Singapore

Parallel 3

8. Strategies for Active Targeting by Molecular Recognition (12 min & 3 min Questions)

Chair

Prof. Dr. med. Kewal Jain, Jain PharmaBiotech, Senior Associate Editor, Neurology MedLink Corporation, San Diego (USA), Basel (CH)

While modulation of physico-chemical properties of Nanocarriers can be utilized for rational tissue guidance of nanodrugs, the multitude of different cell types in a diseased tissue poses another level of challenges. Active targeting of diseased cells or specialized cell subpopulations therefore attracted enormous attention. Apart from the classical targeting functionalities such as antibodies and ligand-mimicking peptides a great diversity of novel related and unrelated targeting moieties is presently in development and under investigation for improvement and personalization of nanodrugs. This includes novel antibody-like or peptide classes such as Nanobodies and knottins, but also nucleic acid-based aptamers and small molecular compounds for targeted delivery. The session will reflect the most actual state of the art in this exciting field with groundbreaking potential.

13.45

The Various Options for Targeting – a short Overview

Prof. Dr. med. Kewal Jain, Jain, PharmaBiotech, Senior Associate Editor, Neurology MedLink Corporation, San Diego (USA), Basel (CH)

14.00

Active Targeting as Modulators of Nanomedicines Pharmacokinetic Profiles

Prof. Dr. med. Simo Schwartz, Jr., PhD, Director Molecular Biology and Biochemistry, Research Center for Nanomedicine (CIBBIM-Nanomedicine) Univ. Hospital Vall d'Hebron and Vall d'Hebron Institut de Recerca (VHIR), Barcelona (E)

- 14.15 **Bioinspired Exosome-mimetic Nanovesicles for Targeted Delivery of Chemotherapeutics**
Dr. Su-Chul Jang, Researcher, Krefting Research Centre, Department of Internal Medicine and Clinical Nutrition, University of Gothenburg, Gothenburg, (S)
- 14.30 **Nanobodies in Medical Diagnostics: New Tools for Reviewing Old Concepts**
Prof. Dr. Christina G. Siontorou BSc (Hons), Assistant Professor, Biomedical Sciences, PhD Analytical Chemistry, Department of Industrial Management & Technology School of Maritime & Industry University of Piraeus, Piraeus (GR)
- 14.45 **New Antibody Derivatives for Targeted Payload Delivery**
Dr. Felix Schumacher, Senior Scientist, Lead Identification, Roche Innovation Center Penzberg, Roche Diagnostics GmbH, Penzberg (D)
- 15.00 **Modified Aptamers as Replacement for Antibodies in Diagnostics and Therapeutics**
Dr. David Bunka CTO, APTAMER Group, Heslington, York (UK)
- 15.15 **Seligo™: A New Class of Customizable Affinity Reagents for Diagnostics and Therapeutics**
Dr. John R. Thornback, Managing Director, Apta Biosciences Pte Ltd, Singapore (SGP)
- 15.30 **The Invention of Spiegelmers to Overcome Stability Issues of Oligonucleotide Aptamers**
Dr. Sven Klussmann, Chief Scientific Officer, NOXXON Pharma AG, Berlin (D)
- 15.45 **Development of Nanoparticles for Clinical Use: Importance of Degradation and Excretion**
Dr. Tore Skotland, Centre for Cancer Biomedicine, Institute for Cancer Research, Oslo University Hospital and University of Oslo (N)

16.00 **Questions and Debate**

16.30 **Break**

Monday, Hall Rio

Parallel 4
 Chair

9. Small Speeches on Posters and from University Village Presentations University

Dr. Sc. Nat. Ruth Schmid, Vice President Marketing, SINTEF Materials and Chemistry, Biotechnology and Nanomedicine, Polymer Particles and Surface Chemistry, Trondheim (N)

13.45 Poster Submitters and Posters and Results of Scientists at Universities participating in the University Village 2016 can apply for a small speech of 4 minutes, serving to highlight the research activities in Nanotechnology / Health. The speeches comprise a maximum of three slides. • Slide 1: general introduction to the topic future and outlook on translation of the work presented in a way that is accessible to the highly inter-disciplinary audience. • Slide 2: some of the highlights of submitters work and institutions work. • Slide 3: The prove, how the work at the university / institute fits into the area of Nanomedicine and Targeted Medicine including showing the future and outlook on translation of the work.

16.30 **Break**

Section 3 Satellite 1: Biomedical Sensing and Analytics

Monday, Hall Osaka

Satellite
 Chair

10. Nanotechnology based Biomedical Sensing and Analytics (12 min & 3 min Questions)

Prof. Dr. Bert Müller, Thomas Straumann-Chair for Materials Science in Medicine, University Basel (CH)

The miniaturization of techniques led to the realization of diagnostic tools, including biomedical sensors. The rapid progress in miniature devices and instrumentation development significantly impacts the practice of medical care as well as future advances. Biomedical analytics as science of developing and applying computable algorithms based on mathematics, operations research, statistics and computer science enables to elaborate and process properties from biological and medical data that suggest clinical and translational research in the field of medicine, improving patient outcomes. This session elucidates some aspects regarding this promising approach and includes the presentation of existing solutions.

- 13.45 **Epithelial Tissues Engineered in Vitro that Bear the Hallmarks of Living Tissue Can Recapitulate Cancer Invasion**
Dr. Marija Plodinec, PhD Project Leader /Senior Scientist, Institute of Pathology, University Hospital Basel, Basel (CH)
- 14.00 **Entry of Nanoparticles into Cells: Mechanisms and Consequences**
Prof. Dr. Kirsten Sandvig, Centre for Cancer Biomedicine, Institute for Cancer Research, the Norwegian Radium Hospital, Oslo, University Hospital and University of Oslo, Oslo (N)
- 14.15 **Quantification of Nanoparticle Uptake by Cells Using Microscopical and Analytical Techniques**
Prof. Barbara Rothen-Rutishauser, Adolphe Merkle Institute, University of Fribourg (CH)
- 14.30 **Polymeric Micro-cantilever Arrays for Detecting DNA Fragments and Biologically Relevant Metal Ions**
Dr. Prabitha Urwyler, ARTORG initiative University of Berne (CH)
- 14.45 **Plasma-induced Nano-wrinkles for Dielectric Artificial Muscles**
Bekim Osmani, BMC University of Basel (CH)
- 15.00 **On-chip Biochemical Sensing Using Si Nanoribbon Field-effect Transistors**
PD Dr. Michel Calame Department of Physics & Swiss Nanoscience Institute University of Basel (CH)
- 15.15 **Recent Developments in Measurement for Nanomedicine**
Hans van der Voorn, BE (Hons), CEO, IZON SCIENCE Ltd, Christchurch (NZL)
- 15.30 **Update on Nanoparticle Tracking (NTA): Quantification of Sub-populations with Regard to Size, Concentration, Zeta potential and Fluorescence**
Dr. Clemens Helmbrecht, head of R&D, Particle Metrix GmbH, Meerbusch (D)
- 15.45 **Multicolor Superresolution STED Microscopy from its Inventors- turn-key, Live Cell, 30nm Resolution**
Dr. Joachim Fischer, Product Manager, Abberior Instruments GmbH, Göttingen (D)
- 16.00 **Nanomechanical Profiling of Breast Cancer – a Novel Tool for Cancer Diagnosis and Prognostics**
Dr. med. Marko Loparic, PhD, Chief Medical Officer; Nuomedis AG, Liestal (CH)
- 16.15 **Further Questions and Debate**
- 16.30 **Break**

Section 4: Plenary Session

Monday, Hall Montreal

- Plenary Chair** **11. Pushing the Limits of Nanomedicine** (25 min & 5 min for questions)
Dr. med. h.c. Beat Löffler, MA, CEO of the European Foundation for Clinical Nanomedicine, Basel (CH)
- 17.00 **Translation from Finding to Product**
Dr. Anil Patri, Chair, Nanotechnology Task Force, Director, NCTR-ORA Nanotechnology Core Facility, U.S. Food and Drug Administration, National Center for Toxicological Research (NCTR), Jefferson, Arkansas (USA)
- 17.25 **First Questions**
- 17.30 **Going Successfully to Clinic with AFM Sensors**
Prof. Dr. Christoph Gerber, Director of Scientific Communication, Swiss Nanoscience Institute, University of Basel, Basel (CH)
- 17.55 **First Questions**
- 18.00 **Learning out of the Failures of the Past – A new Strategy for Treating Cancer**
Prof. Dr. Shmuel (Muli) Ben-Sasson School of Medicine-IMRIC-Developmental Biology and Cancer Research, Faculty of Medicine, Experimental Medicine and Cancer Research, Hebrew University of Jerusalem (IL)

- 18.25 **First Questions**
- 18.30 **Further Questions and Debate**
- 18.45 **End of Day 1**
- 19.30 **We Meet in Front of Swissôtel Le Plaza**
- 19.45 **Departure by event-own Tramway to Riehen**
- 20.00 **Brokerage Evening Event with Cultural Moments at Landgasthof in Riehen**

Tuesday, June 28, 2016

Section 5: 4 Parallel Sessions

- Tuesday, Hall Montreal
- Parallel 1**
Chair
- 12. Pediatric Nanomedicine**
Prof. Dr. Alejandro Sosnik, Pharmacist, Ph.D., Associate Professor, Department of Materials Science and Engineering, Technion-Israel Institute of Technology, Technion City, Haifa (IL)
 - 08.15 **Paediatric Nanomedicine: Challenges to Close the Adult-child Gap Before it Emerges**
Prof. Dr. Alejandro Sosnik, Pharmacist, Ph.D., Associate Professor, Department of Materials Science and Engineering, Technion-Israel Institute of Technology, Technion City, Haifa (IL)
 - 08.30 **The Challenges of Pediatric Cancer and the Opportunities to Overcome them with Nanomedicines**
Dr. Angel Carcaboso, Department of Oncology, Sant Joan de Déu Hospital, Barcelona (ES)
 - 08.45 **The Application of Nanomedicine in Paediatric Infectious Diseases: Focus on HIV**
Prof. Dr. Andrew Owen, BSc, MSc, PhD, FSB, Professor for Molecular and Clinical Pharmacology, University of Liverpool, Liverpool (UK)
 - 09.00 **Questions and Debate**
 - 09.30 **Break**
- Tuesday, Hall Sydney
- Parallel 2**
Chair
- 13. Computational Modelling and Design in Nanomedicine** (12 min & 3 min Questions)
Prof. Dr. Giacinto Scoles, Department of Medical and Biological Sciences, University Hospital, University of Udine, Udine (I) and Biology Department, Temple University, Philadelphia, PA (USA)
 - 08.15 **Computational Design of Peptide based Architectures for Biomarker Recognition**
Prof. Dr. Sara Fortuna, Coordinator of the Theory section of the Molecular Nanotechnology for Life Science Applications (MONALISA) group, Department of Biological and Medical Sciences, University of Udine, Contract professor of Practical Informatics, Department of Chemical and Pharmaceutical Sciences, University of Trieste (I)
 - 08.30 **Biomedical Simulations in the Development of a Mechano-sensitive Drug Delivery System**
Dr. Simone Hieber, Research Associate, Biomaterials Science Center, University of Basel, Allschwil (CH)
 - 08.45 **Precision Design and Personalized Application: A “Bench to Bedside” Nanoplatfrom to Overcome Low Gemcitabine Chemo-sensitivity**
Prof. Dr. Guangjun Nie, Professor of Nanobiology and Medicine, National Center for Nanoscience and Technology, China, Beijing (CHN)

09.00 **Modeling Bio-Nanomedicine Interactions**
Prof. Dr. Wolfgang Wenzel, Research Leader Nanoscale and Biomolecular Simulation, Karlsruhe Institute of Technology (KIT), Karlsruhe (D)

09.15 **Questions and Debate**

09.30 **Break**

Tuesday, Hall Singapore

Parallel 3 **14. Nanomedicines: In Vitro-in Vivo Correlations** (12 min & 3 min Questions)

Chair **Prof. Dr. David Stepensky**, Senior Lecturer, Assistant Professor, Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva (IL)

08.15 **Efficiency of Nanoformulations Targeting to their Site of Action and the Factors that Govern it**
Prof. Dr. David Stepensky, Senior Lecturer, Assistant Professor, Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva (IL)

08.30 **Super Stealth Liposomes for Drug Delivery**
Dr. Joy Wolfram, Department of Nanomedicine, The Methodist Hospital Research Institute, Houston, TX (USA); CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, National Center for Nanoscience & Technology of China, Beijing (CHN)

08.45 **Nanoconstructs for Theranosis: From in Silico/in Vitro Studies to Preclinical Models**
Prof. Dr. Paolo Decuzzi, Senior Researcher and Professor, Director of the Laboratory of Nanotechnology for Precision Medicine, Italian Institute of Technology, Genova (I)

09.00 **Reliability of in Vivo Models in Predicting Nanomedicine-mediated Infusion-related Reactions in Humans**
Prof. Dr. S. Moein Moghimi, FloN, Professor of Nanomedicine and Director, Centre for Pharmaceutical Nanotechnology and Nanotoxicology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen (DK)

09.15 **Structure-Function Relationships of Nano-Bio-Interaction**
Prof. Dr. med. Patrick Hunziker, Deputy Chief of the Intensive Care Clinic, University Hospital Basel (CH)

Questions and Debate after each talk

09.30 **Break**

Tuesday, Hall Rio

Parallel 4 **15. The Big Picture of Nanomedicine** (11 min & 4 min Questions)

Chair **Prof. Dr. Lajos P. Balogh**, AA Nanomedicine and Nanotechnology Consultants, North Andover, Massachusetts and Member of the Executive Board, American Society for Nanomedicine, Boston (USA)

08.15 **Networks, Emergence, HIV, and Cancer**
Prof. Dr. Lajos P. Balogh, AA Nanomedicine and Nanotechnology Consultants, North Andover, Massachusetts and Member of the Executive Board, American Society for Nanomedicine, Boston (USA)

08.30 **ENATRANS - Enabling Nanomedicine Translation**
Nicolas Gouze, VDI/VDE-IT, Coordinator of the Coordination & Support Action ENATRANS - Enabling Nanomedicine Translation, Berlin (D)

08.45 **Novel Approaches for Industry & Academia Cooperation in Regenerative Medicine**
Dr. Rudolf Frycek PhD, AMIRES and Contipro, Prague (CZ)

09.00 **Nanomedicine: Treating Humans, Animals and Crops**
Prof. Dr. Avi Schroeder, PhD, Assistant Professor of Chemical Engineering, Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Technion; Israel Institute of Technology, Haifa (IL)

09.15 **What Ethical Questions will Nanomedicine Face Next?**
Dr. Donald Bruce, Managing Director, Edinethics Ltd., Edinburgh (UK).

Questions and Debate after each intervention

09.30 **Break**

Section 6: 4 Parallel Sessions

Tuesday, Hall Montreal

Parallel 1 **16. Pharmaceutical Development of Nanomedicine Medications** (12 min & 3 min Questions)
Session established in collaboration with the International Association for Pharmaceutical Technology (APV), Mainz (D)
Chair **Dr. Bernd Riebesehl**, Principal Fellow, Novartis Pharma AG, Basel (CH)

10.00 **Nanomedicines to Enable Innovative Cancer Medicines**
Dr. Marianne Ashford PhD, Principal Scientist Drug Targeting, Pharmaceutical Development
AstraZeneca, Macclesfield, Cheshire (UK)

10.15 **Micro Dispensing of Drug Nanosuspensions for Personalized Medicine**
Bastian Bonhoeffer, MSc, PhD Student, Novartis Pharma, PDU Oral, Novartis Pharma AG, Basel (CH)

10.30 **Transport, Degradation and Drug Release Mechanisms of Nanomedicines**
PD Dr. Peter van Hoogevest, Lipoid GmbH, Scientific Department, Ludwigshafen (D)

0.45 **Nanocort Pegylated Liposomal Prednisolone: Clinical Experience in Inflammatory Disease**
Dr. Josbert M. Metselaar PharmD, PhD, Dept. of Experimental Molecular Imaging, RWTH Aachen
University Clinic (D) and CEO Enceladus Pharmaceuticals, Naarden (NL)

11.00 **Learning how to Increase Clinical Translation for (Nano-) Medicine**
Dr. Werner Cautreels, CEO, Selecta Biosciences Watertown /Boston, MA (USA)

11.15 **The Nanomedicines Alliance – How Industry Builds its Network – First Achievements**
Dr. med. Frank J. Malinoski, Chief Medical Officer, Liquidia Technologies, Vice Chair, Nanomedicines,
Research Triangle Park, NC (USA)

11.30 **Further Questions and Debate**

11.50 **Change for Plenary Session, Hall Montreal**

Tuesday, Hall Sydney

Parallel 2 **17. Gene Editing for Nanomedical Approaches**
Chair **Dr. Chris Torrance**, CEO, PhoreMost Ltd., Cambridge (UK)

10.00 **Genome-wide Target-ID and Validation Techniques for Novel Drug Discovery** (15 min & 5 min questions)
Dr. Chris Torrance, CEO, PhoreMost Ltd., Cambridge (UK)

10.20 **Polymeric Nanocarriers for In-vivo Genome Editing Using Nuclease Encoding mRNA**
Prof. Dr. Claus-Michael Lehr, Head, Department of Drug Delivery (DDEL), Helmholtz-Institute
for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI), Saarland
University, Saarbrücken (D)

10.40 **CRISPR-Cas: From Bacterial Immunity System to a Versatile and Universal Tool for Genome Editing
and Regulation**
Dr. Ümit Pul, Research Scientist, Project Manager, Platform Coordinator Genome Editing, B.R.A.I.N. ,
Zwingenberg (D)

11.00 **CRISPR Based Synthetic Lethality Screening to Identify Novel Anticancer Targets**
Dr. Bastiaan Evers, Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam (NL)

11.20 **Further Questions and Debate**

11.40 **Change for Plenary Session, Hall Montreal**

Tuesday, Hall Singapore (Part A 10.00 – 11.00)

Parallel 3
Chair
Part A

18. Nanomedicine for Ophthalmic Disease and Otorhinolaryngology

Prof. Dr. med. Herbert A. Reitsamer, PhD, Vice President Austrian Ophthalmological Society, Director Experimental Ophthalmology, Director Glaucoma Service & Glaucoma Prevention Programme SALK/Paracelsus Medical University Salzburg (A)

10.00 **Nanomedicine for Ophthalmic Disease - 2 Case Studies for Translation**

Prof. Dr. Subbu Venkatraman, Professor & Chair, Materials Science & Engineering Director Ocular Therapeutic Engineering Centre, Director, NTU-NWU Institute for Nanomedicine, Singapore, (SGP)

10.15 **Intratympanic Delivery of Nanomaterials for the Inner Ear and the Associated Pathway and Safety**

Prof. Dr. med. Jing Zou, Hearing and Balance Research Unit, Field of Otolaryngology, School of Medicine, University of Tampere, Tampere, (FI) and Department of Otolaryngology - Head and Neck Surgery, Center for Otolaryngology - Head & Neck Surgery of Chinese PLA, Changhai Hospital, Second Military Medical University, Shanghai (CHN)

10.30 **Questions and Debate**

Tuesday, Hall Singapore (Part B 11.00 – 11.50)

Parallel 3
Chair
Part B

19 Graphene in Nanomedicine and Nanotoxicology

Dr. Khuloud T. Al-Jamal, Reader in Nanomedicine, Drug Delivery Group, Institute of Pharmaceutical Science, King's College London, London (UK)

10.50 **Introduction**

Dr. Khuloud T. Al-Jamal, Reader in Nanomedicine, Drug Delivery Group, Institute of Pharmaceutical Science, King's College London, London (UK)

11.00 **Making Versatile Double- Clicking Graphene Oxide for drug Delivery Applications**

Kuo-Ching Mei, Institute of Pharmaceutical Science, King's College London (UK)

11.15 **Cellular Responses to Graphene Oxide Sheets: Effect of Lateral Dimension and the Oxidative Stress Paradigm**

Dr. Sandra Vranic, Nanomedicine Lab, Faculty of Medical & Human Sciences & National Graphene Institute, University of Manchester, Manchester (UK)

11.30 **Questions and Debate**

11.40 **Change for Plenary Session, Hall Montreal**

Tuesday, Hall Rio

Parallel 4
Chair

20. Assessing Equivalence of Complex Drug Products: Experience with Follow-on Nanomedicines and Non-biological Complex Drugs (NBCDs)

Prof. Dr. Daan J.A. Crommelin, Emeritus Professor at the Department of Pharmaceutics, Utrecht University (NL), Adjunct Professor at the Department of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah (USA) Co-founder of Octopus, Leiden (NL) AND
Prof. Dr. Stefan Mühlebach Chief Scientific Officer, Vifor Pharma Ltd, Villars-sur-Glâne, Professor of Pharmaceutical Sciences, University of Basel, Basel (CH)

10.00 **View and Update from EMA**

Prof. Dr. med. Marisa Papaluca, Senior Scientific Advisor, Human Medicines Research & Development Support Division, London (UK)

10.15 **View and Update from FDA**

Dr. med. Frank F. Weichold, Ph.D., Director of Critical Path and Regulatory Science Initiatives, Office of Regulatory Science & Innovation (ORSI) and Office of the Chief Scientist / Office of the Commissioner Food and Drug Administration (FDA), Silver Spring, MD (USA)

- 10.30 **View from the NCL**
Dr. Scott E. McNeil, Director, Nanotechnology Characterization Laboratory, National Cancer Institute, Vice President, Leidos Biomedical Research, Inc., Frederick, (USA)
- 10.45 **Compendial Initiatives for NBCDs**
Prof. Dr. Gerrit Borchard, Professor Biopharmaceutical Sciences, President of the Swiss Society of Pharmaceutical Sciences, Vice President of the European Federation of Pharmaceutical Sciences, School of Pharmaceutical Sciences, Universities of Geneva and Lausanne (CH)
- 11.00 **Ocular Emulsions**
Dr. Sessa Neervannan, Senior Vice President, Pharmaceutical Development Allergan Inc. Orange County (USA)
- 11.15 **Questions and Debate**
- 11.40 **Change for Plenary Session, Hall Montreal**

Section 7 Plenary Session

- Tuesday, Hall Montreal
- Plenary Chair **21. Advanced Image Analysis**
Prof. Dr. med. Simo Schwartz, Jr., PhD, Director Molecular Biology and Biochemistry, Research Center for Nanomedicine (CIBBIM-Nanomedicine) University Hospital Vall d'Hebron and Vall d'Hebron Institut de Recerca (VHIR) Barcelona (ES)
- Keynote Lecture
- 11.50 **Tissue Phenomics - Predicting Drug Response for Cancer Immunotherapy**
Prof. Dr. Gerd Binnig, Nobel Laureate, Founder of Definiens AG, Munich (DE)
- 12.20 **Questions and Debate**
- 12.30 **Lunch**

Section 8: Satellite 2: Regulatory Authorities Closed Lunch

- Satellite **22. CLOSED Meeting of the Regulatory Authorities, Separate Lunch, Room Miami (12.40)**

Section 9: 4 Parallel Sessions

- Tuesday, Hall Montreal
- Parallel 1 Chair **23. Cancer Nanomedicine in Diagnostica & Therapy (20 min & 5 min Questions)**
Prof. Dr. med. Simo Schwartz, Jr., PhD, Director Molecular Biology and Biochemistry, Research Center for Nanomedicine (CIBBIM-Nanomedicine) University Hospital Vall d'Hebron and Vall d'Hebron Institut de Recerca (VHIR), Barcelona (ES)
- 13.40 **Increasing Sensitivity of Tumor Cells to Treatment with Nanomedicines**
Prof. Dr. med. Simo Schwartz, Jr., PhD, Director Molecular Biology and Biochemistry, Research Center for Nanomedicine (CIBBIM-Nanomedicine) University Hospital Vall d'Hebron and Vall d'Hebron Institut de Recerca (VHIR), Barcelona (ES)
- 14.05 **Harnessing RNAi-nanomedicines for Therapeutic Intervention in Hematological Malignancies**
Prof. Dr. Dan Peer, Head, Laboratory of Nanomedicine; Dept. of Cell Research & Immunology, and Dept. of Materials Science & Engineering, Director, FTA: Nanomedicines for Personalized Theranostics, Director, Leona M. and Harry B. Helmsley Nanotechnology Research Fund, Tel Aviv University, Tel-Aviv (IL)

- 14.30 **Role of Pancreatic Cancer-derived Exosomes**
Prof. Dr. Debabrata Mukhopadhyay, Professor of Biochemistry and Molecular Biology, Associate Director of the Mayo Clinic Comprehensive Cancer Center, Mayo Clinic College of Medicine, Associate Director of both, Tumor Microenvironment and Nanomedicine programs, Associate Director of Mayo Clinic Comprehensive Cancer Center for Global Alliances, Mayo Clinic College of Medicine, Rochester, MN. (USA)
- 14.55 **Differentiating Between Cancer and Inflammation: Gold Nanoparticles Offer CT Imaging of Metabolic Activity**
Prof. Dr. Rachela Popovtzer, Faculty of Engineering & The Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat Gan (IL)
- 15.20 **Therapeutic Effects of Trehalose Liposomes Against Lymphoblastic Leukemia along with Apoptosis in Vitro and in Vivo**
Prof. Dr. Yoko Matsumoto, Sojo University, Department of Life Sciences, Nishi-ku Kumamoto (J)
- 15.45 **Questions & Debate**
- 16.00 **Break**
- Tuesday, Hall Sydney
- Parallel 2
Chair **24. Immunogenicity Toxicity and Safety of Nanoparticles (12 min & 3 min Questions)**
Prof. Dr. med. Janos Szebeni, Head of the Nanomedicine Research and Education Center, Semmelweis University, Budapest (H) and **Dr. Marina A. Dobrovolskaia**, Ph.D. Principal Scientist, Section Head, Immunology Nanotechnology Characterization Lab, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick MD (USA)
- 13.40 **Short-term Immune Suppression and Long-term Immunogenicity of PEGylated Liposomes in pigs: A New Functional Model of Nanoparticle Immunogenicity**
Prof. Dr. med. Janos Szebeni, Head of the Nanomedicine Research and Education Center, Semmelweis University, Budapest (H)
- 13.55 **Comparison of the Animal Models of Complement Activation Related Pseudoallergy**
Dr. habil. Laszlo Dezsi, Senior Researcher, Nanomedicine Research and Education Center, Semmelweis University, Budapest (H)
- 14.10 **Challenges and Considerations for the Detection of Endotoxin in Nanomedicines**
Dr. Marina A. Dobrovolskaia, Ph.D. Principal Scientist, Section Head, Immunology Nanotechnology Characterization Lab, Leidos Biomedical Research Inc. Frederick National Laboratory for Cancer, Frederick (USA)
- 14.25 **Leukolike Technology to Avoid Nanoparticle Recognition by the Immune System**
Dr. Ennio Tasciotti, PhD, Associate Professor of Nanomedicine, Institute for Academic Medicine, Houston Methodist Hospital Research Institute; Director, Center for Biomimetic Medicine ; Scientific Director, Surgical Advanced Technology Laboratory, Houston, TX (USA)
- 14.40 **Regulatory Considerations for Immune Toxicity Studies of Nanomedicines**
Dr. med. Frank Weichold U.S. Food and Drug Administration, Washington, Washington, D.C. (USA)
- 14.55 **Nanoparticle and the Assessment of Endocrine Disrupting Effects**
Dr. rer. nat. Reinhard Möller, Sales and Marketing Manager, TECOMedical Ltd. Sissach (CH)
- 15.10 **Cytokines and Nanoparticles: a Translational Case Study**
Dr. Marina A. Dobrovolskaia, Ph.D. Principal Scientist, Section Head, Immunology Nanotechnology Characterization Lab, Frederick National Laboratory for Cancer, Frederick (USA)

- 15.25 **Graphene Oxide Interactions with Innate Immune Cells; Neutrophil Biodegradation and Inflammasome Activation**
Prof. Dr. Bengt Fadeel, Research group leader, Nanosafety & Nanomedicine Laboratory, Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, (S)
- 15.40 **Questions and Debate**
- 16.00 **Break**
- Tuesday, Hall Singapore
- Parallel 3 **25. Rare and Neglected Diseases**
Chair **Prof. Dr. Reto Brun**, Head Parasite Chemotherapy, Swiss Tropical and Public Health Institute, Basel (CH)
- 13.40 **Neglected Diseases: Current Status and Future Needs**
Prof. Dr. Reto Brun, Head Parasite Chemotherapy, Swiss Tropical and Public Health Institute, Basel (CH)
- 13.55 **Malaria Drug Discovery: an Update**
Prof. Dr. Paul Herrling, Chairman of the Board of the Novartis Institute for Tropical Diseases, Singapore (SGP) and Vice-President of the ETH Board, Zürich (CH)
- 14.15 **Loading Antimalarial Drugs into Non-infected Red Blood Cells: an Undesirable Roommate for Plasmodium**
Prof. Dr. Xavier Fernàndez Busquets, PhD, Nanomalaria Joint Unit, Associate, Institute for Bioengineering of Catalonia, Barcelona, Member of the Barcelona Centre for International Health Research, Barcelona (ES)
- 14.30 **A Point-of-care Diagnostic Platform for Infectious Diseases DiscoGnosis Final Report**
Dr. Mohammed Bakheit R&D Scientist, Mast Diagnostica GmbH, Partner in DiscoGnosis, Reinfeld (D)
- 14.45 **Lung Delivery: Nebulizable Macrophage Targeted pH-sensitive Nanohalosomes can make a Difference**
Prof. Dr. Eder Lilia Romero, Programa de Nanomedicinas, Universidad Nacional de Quilmes, Buenos Aires (AR)
- 15.00 **Nanosopic Findings in Rectal Mucosa/Tissue in Patients with HIV/AIDS**
Dr. med. Maria Annunziato, Presidente Fundador de la Asociación Latinoamericana de Nanomedicina Clínica, Caracas (VEN)
- 15.15 **The Zika Virus Epidemic: Why Now and What are the Does and Don'ts**
Prof. Dr. Hans H. Hirsch, Department of Biomedicine, University of Basel, Basel (CH)
- 15.30 **Self-nanoemulsifying Drug Delivery Systems of Artemether and Lumefantrine**
Prof. Anthony A. Attama, Drug Delivery and Nanomedicines Research Group, Department of Pharmaceutics and Pharm. Microbiology, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka (NGA)
- 15.45 **Questions and Debate**
- 16.00 **Break**
- Tuesday, Hall Rio
- Parallel 4 **26. Nanodrug Delivery: Novel Insights and Strategies** (12 min & 3 min for Questions)
Chair **Prof. Dr. med. Dong Soo Lee**, PhD. Chairman Department of Nuclear Medicine Seoul National University Seoul (KOR)
- 13.40 **What Happens to Nanoparticles After they have been Internalized by Cells?**
Prof. Dr. Wolfgang J. Parak, Department of Physics, Philipps University of Marburg, Marburg an der Lahn (D) and CIC Biomagune, San Sebastian (ES)
- 13.55 **Doxorubicin-Functionalized Dextran-Based Single Chain Polymeric Nanoparticles as New Potential Therapeutic Nanosystems**
Dr. Marco Marradi, Senior Researcher, Biomaterials, Unit IK4-CIDETEC Research Center, San Sebastián (ES)

- 14.10 **Penetration Enhancers for better Effectiveness of Intra-Tumoral Anti-Cancer Drug Delivery Systems**
Hen Popilski, M. MedSc Student, Department of Clinical Biochemistry and Pharmacology Ben-Gurion University of the Negev, Beer-Sheva (IL)
- 14.25 **Reversible Esterification-based Liposomal Loading for Enhanced Retention of Hydrophobic Drugs**
Dr. Steve R. Roffler, Research Fellow and Division Coordinator of the Cancer Division in the Institute of Biomedical Sciences, Academia Sinica in Taipei, (TW)
- 14.40 **Prolonged Intracellular Accumulation of Light-activatable Nanoparticles in Leukemic Cells Allows Remote Activation**
Dr. Lino Ferreira, Principal Investigator, Center for Neurosciences and Cell Biology, University of Coimbra, Coimbra (P)
- 14.55 **Multifunctional Nanoplatfom for Drug Delivery Carrying CIS-Pt. Magnetic Nanoparticles and Luminescence Thermometry**
Dr. Angel Millan, PhD, Tenure Researcher, Instituto de Ciencia de Materiales de Aragón (CSIC) Zaragoza (E)
- 15.10 **Controlling Biodistributions with Glycan-targeted Liposomes – Aiming for Tumors and Beyond**
Dr. Stefan Halbherr, Manager Research and Development, InnoMedica Holding AG, Bern (CH)
- 15.25 **Questions and Debate**
- 16.00 **Break**

Section 10: Satellite 3 Dendrimer based Results

- Tuesday, Hall Osaka
- Satellite
Chair **27. Advanced Dendrimer Based Results in Medicine**
Prof. Dr. Donald Tomalia, Distinguished Visiting Professor, Columbia University, NY, Affiliate Professor, Virginia Commonwealth University, Richmond, Adjunct Professor, University of Pennsylvania, Philadelphia, CEO & Founder NanoSynthons LLC, National Dendrimer & Nanotechnology Center Mt. Pleasant, MI (USA)
- 13.40 **Introduction to the Satellite**
Prof. Dr. Donald Tomalia, Distinguished Visiting Professor, Columbia University, NY, Affiliate Professor, Virginia Commonwealth University, Richmond, Adjunct Professor, University of Pennsylvania, Philadelphia, CEO & Founder NanoSynthons LLC, National Dendrimer & Nanotechnology Center Mt. Pleasant, MI (USA)
- 13.55 **Phosphorus Dendrimers in Photodynamic Therapy**
Prof. Dr. Barbara Klajnert-Maculewicz, Department of General Biophysics, University of Lodz, (PL)
- 14.10 **Anti-inflammatory Primate Studies related to Tropical Diarrhea**
Prof. Dr. med. Sunil Shaunak, MD, PhD, FRCP, FRCPE, FRCPath, FRSC, Professor of Infectious Diseases, Consultant Physician in Medicine & Infectious Diseases Faculty of Medicine, Imperial College London, Hammersmith Hospital, London (UK)
- 14.25 **Antiinflammatory Dendrimers with Potential Use in the Treatment of Multiple Sclerosis**
Prof. Dr. Valentin Ceña, Unidad Asociada Neurodeath, Universidad de Castilla-La Mancha, Facultad de Medicina Farmacología, Albacete (ES)
- 14.40 **Phosphorus Dendrimer-based Anti-inflammatory Properties for the Treatment of Diseases**
Prof. em. Dr. Jean-Pierre Majoral, Laboratoire de Chimie de Coordination de Toulouse, Toulouse (F)
- 14.55 **Hepatocellular Nuclear Factor 4 α (HNF-4 α) Activation by saRNA Rescues Dyslipidemia and Promotes Favorable Metabolic Profile in a High Fat Diet (HFD) Fed Rat Model**
Dr. Vikash Reebye, Senior Research Fellow, MiNA Therapeutics, Department of Surgery and Cancer, Hammersmith Hospital, Imperial College London, London (UK)

- 15.10 **Dendronized Superparamagnetic Nanoparticles as Tools for MRI, Efficient in Vivo Cancer Targeting and Magnetic Hyperthermia Treatment**
Dr. Delphine Felder-Flesch, CNRS Research Associate Institute of Physics and Chemistry of Materials of Strasbourg, Strasbourg (F)
- 15.25 **Dendrimers in Nanomedicine: It Is Time to Meet the Expectations**
Prof. Dr. Catia Ornelas, University of Campinas – UNICAMP, Cidade Universitaria Zeferino, Vaz Campinas (BR)
- 15.40 **Questions and Debate**
- 16.00 **Break**

Section 11: Plenary Session

- Tuesday, Hall Montreal
- Plenary Chair **28. The Regulatory Authorities' Voice 2016**
Dr. med. Fergal Donnelly MSc FFPM, Principal Scientific Officer in the Advanced Materials and Nanotechnologies, Unit of the Industrial Technologies Directorate of the Research, Directorate-General of the European Commission, Brussels (B)
- 16.30 **Europe: Prof. Dr. med. Marisa Papaluca**, Senior Scientific Advisor, Human Medicines Research & Development Support Division, London (UK)
- Japan: Dr. Kumiko Sakai-Kato**, Section Head, Division of Drugs, National Institute of Health Sciences (NIHS), Ministry of Health, Labour and Welfare (MHLW), Tokyo (J)
- Canada: Hripsime Shahbazian, MSc**, Senior Science Advisor, Office of Science, Therapeutic Products Directorate, Health Canada, Ottawa (CND)
- China: Prof. Dr. Guangjun Nie**, Professor of Nanobiology and Medicine, National Center for Nanoscience and Technology, China, Beijing (CHN)
- USA: Dr. med. Frank F. Weichold, Ph.D.**, Director of Critical Path and Regulatory Science Initiatives, Office of Regulatory Science & Innovation (ORSI) and Office of the Chief Scientist / Office of the Commissioner Food and Drug Administration (FDA), Silver Spring, MD (USA)
- India: Dr. Sitaramaiah Mokkapati**, President Indian Nanomedicine Society, Former Deputy Director-General in the Division of Reproductive Health and Nutrition at Headquarters, Indian Council of Medical Research, New Delhi (IN)
- Africa: Dr. Paul Orhii**, National Agency for Food and Drug Administration and Control (NAFDAC), Abuja, Nigeria (AFR)
- 18.00 **Questions & Debate**
- 18.30 **29. Aperitif & Prize-giving for best Posters in 3 categories**
Awarding the poster prizes for the best 3 Posters in the 3 categories & Apéritif
• Basic Nanomedicine, • Translational Nanomedicine • Nanotoxicology and Nano-Bio-Characterization
- 19.15 **End of Day 2**
- 19.45 **Speakers and Invited Guests Meet in Front of Swissôtel Le Plaza**
- 20.00 **Speakers Dinner**

Wednesday, June 29, 2016

Section 12 : 4 Parallel Sessions

- Wednesday, Hall Montreal
- Parallel 1
Chair
- 30. Late Breaking and Ongoing Clinical Trials 1 (12 min & 3 min for Questions)**
Dr. Heinrich Haas, Vice President Drug Delivery, BioNTech RNA Pharmaceuticals GmbH, Mainz (D)
- 08.15 **Update on New Clinical Studies with Abraxane**
Dr. Neil Desai, VP Strategic Platforms, Celgene Corporation, Los Angeles (USA)
- 08.30 **CriPec Nanomedicines: Principles, Preparation, Preclinical Evaluation and Early Clinical Translation**
Dr. Cristianne JF Rijcken, PharmD PhD, Founder and CSO, Crystal Delivery, Maastricht (NL)
- 08.45 **Preclinical and Clinical Experience with Promitil, a Nano-formulation of a Liposomal Anti-cancer Prodrug**
Prof. Dr. med. Alberto A. Gabizon, Hebrew University - School of Medicine - Shaare Zedek MC Oncology Institute, Jerusalem (IL)
- 09.00 **Novel Linkers for Anticancer Protein Conjugates**
Dr. Felix Kratz, Ph.D., Vice President of Drug Discovery, CytRx Corporation, Drug Discovery Branch Innovation Center Freiburg, Freiburg i. Breisgau (D)
- 09.15 **New Clinical Directions with ABI-009, a Targeted Nanoparticle mTOR Inhibitor**
Dr. Neil Desai, CEO, AADi LLC, Los Angeles (USA)
- 09.30 **Further Questions and Debate**
- 09.45 **Break**
- Wednesday, Hall Sydney,
- Parallel 2
Chair
- 31. Nanomedical Approaches and Mechanisms in Infectious and Inflammatory Disease**
Prof. Dr. Gert Storm, Department Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht and Division Imaging, University Medical Center Utrecht (UMCU and Targeted Therapeutics, MIRA Institute for Biomedical technology and Technical Medicine, University of Twente (NL)
- 08.15 **Liposomal Corticosteroids in a Rabbit Model of Non-infectious Anterior Uveitis**
Prof. Dr. Gert Storm, Department Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht and Division Imaging, University Medical Center Utrecht (UMCU and Targeted Therapeutics, MIRA Institute for Biomedical technology and Technical Medicine, University of Twente (NL)
- 08.25 **Magnetic Blood Purification Revisited!**
Dr. Sc. ETH Inge Herrmann, Research Group Leader, Swiss Federal Laboratories for Materials Science and Technology, St. Gallen (CH)
- 08.35 **Liposome Delivery of M2 Polarizing Agents to Macrophages**
Anne Gauthier, PhD Cnd, Pharmaceutical Development Novartis Pharma AG, Basel (CH)
- 08.45 **Liposome-encapsulated Anti-inflammatory Agents Protect Cardiac Function after Myocardial Infarction: First Preclinical Results**
Dr. Bertrand Czarny, Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore (SGP)
- 09.00 **The Role of Nano-biotechnology in Personalized Management of Infections**
Prof. Dr. med. Kewal Jain, Jain PharmaBiotech, Senior Associate Editor, Neurology MedLink Corporation, San Diego (USA), Basel (CH)
- 09.10 **Questions and Debate**
- 09.45 **Break**

Wednesday, Hall Singapore

Parallel 3

32. Materials Science for Nanomedicine (10 min & 5 min for Questions)

Session established in collaboration with the European Materials Research Society (E-MRS), Strasbourg, (F)

Chair

Prof. Dr. Luisa Torsi, Member of the H2020 Programme Committee of the Italian Ministry for Education and Research, President elect of the European Material Research Society, Coordinator of the Council in Materials Science, University of Bari, Bari (I)

08.15

Iron Oxide Nanoparticles

Prof. Dr.-Ing. Heinrich Hofmann, Director Powder Technology Laboratory, Institute of Material EPFL, Lausanne (CH)

08.30

Printable Bio-electronics for Future Point- of Care Applications

Prof. Dr. Luisa Torsi, President of the European Material Research Society (E-MRS), Member of the H2020 Programme Committee of the Italian Ministry for Education and Research, Department of Chemistry University of Bari, Bari (I).

08.45

The First Story of an OLED Molecule in the Realm of Biological World

Prof. Dr. Dong June Ahn, Professor of KU-KIST Graduate School of Converging Science & Technology, and Depts. of Chemical & Biological Engineering, and Biomicrosystem Technology, College of Engineering, Korea University, President of the Korean Society for Nanomedicine, Seoul (ROK)

09.00

Self-assembling Peptide Nanoparticles (SaPNs): their Use in Biomedical Applications

Prof. Dr. Ueli Aebi, Professor em. of Structural Biology at the Biozentrum Basel and Director of the Maurice E. Müller Institute for Structural Biology, Basel (CH)

08.15

Nanoscience-inspired Materials Research in Dentistry

Prof. Dr. Bert Müller, Thomas Straumann-Chair for Materials Science in Medicine, University Basel(CH)

09.30

Biocompatible Platinum Nanoparticles Restore Physiological ROS Homeostasis in a Real Experimental Model of a Human Cerebrovascular Disease

Dr. Mauro Moglianetti, Senior Researcher, Istituto Italiano di Tecnologia (IIT), Lecce (I)

Questions and Debate after each talk

09.45

Break

Wednesday, Hall Rio

Parallel 4

33. Nanomedical Applications for Diagnostics and Therapy

Chair

Prof. Dr. Wolfgang Wenzel, Research Leader Nanoscale and Bimolecular Simulation, Karlsruhe Institute of Technology (KIT), Karlsruhe (D)

08.15

Micro & Macro Environment Features towards Disease Signature Identification

Dr. Mira Marcus-Kalish, Senior Research Fellow, International Research Affairs, Tel Aviv University (IL)

08.25

Lipid Nanoparticle Mediated RNAi Functional Delivery: a Proof of Concept for Leukemia Nano-therapeutics

Dr. Nidhi Jyotsana Department of Hematology, Hemostasis, Oncology and Stem cell Transplantation, Hannover Medical School, Hannover (D)

08.35

Drug Targeting to Hepatocytes Using Asialofetuin-conjugated Liposomes

Prof. Dr. Jörg Huwyler, Professor of Pharmaceutical Technology, Department of Pharmaceutical Sciences, University of Basel, Basel (CH)

08.45

His-tag-based Controllable Release of Peptide and Protein Drugs

Prof. Dr. Aoneng Cao, Institute of Nanochemistry and Nanobiology, Shanghai University, Shanghai (CHN)

- 08.55 **Modeling Breast Cancer with Tridimensional Biomimetic Scaffolds: Effect of the Microenvironment on Hypoxia Response, Migration, Proliferation, and Drug Resistance**
Dr. Ennio Tasciotti Associate Professor of Nanomedicine, Institute for Academic Medicine, Houston Methodist Hospital Research Institute; Director, Center for Biomimetic Medicine ; Scientific Director, Surgical Advanced Technology Laboratory, Houston, TX (USA)
- 9.05 **Simple, Scalable Nanomedicine Formulation using the Microfluidic Platform with In Vitro and In Vivo Applications in Gene Modulation - From Cell Culture to the Clinic**
Dr. Gesine Heuck, Ph.D., Precision NanoSystems, Inc. Field Application Scientist, Seattle, WA (USA)
- 09.15 **Cell Surface Engineering for Cell Therapy in Cancer**
Prof. Dr. Insung S. Choi, Professor for Organic Chemistry, Ph.D, Harvard University and Department of Chemistry Korea Advanced Institute of Science and Technology (KAIST) Yuseong-gu (ROK)
- 09.25 **Questions and Debate**
- 09.45 **Break**

Section 13 : 4 Parallel Sessions

Wednesday, Hall Montreal

- Parallel 1**
Chair **34. Late Breaking and Ongoing Clinical Trials 2 (12 Minutes plus 3 minutes for Questions)**
Dr. Cristianne JF Rijcken, PharmD PhD, Founder and CSO, Crystal Delivery, Maastricht (NL)
- 10.15 **Novel Peptide-based Delivery for Polynucleotides that Bypass the Endosomal Uptake Pathway**
Dr. Gilles Divita, Aadigen LLC, Los Angeles (USA)
- 10.30 **RNA Nanomedicines for Individualized Tumor Immunotherapy: Patient Trials**
Dr. Heinrich Haas, Vice President Drug Delivery, BioNTech RNA Pharmaceuticals GmbH, Mainz (D)
- 10.45 **Spiegelmers® - The Adolescence of a Novel Compound Class**
 Pre-clinical and clinical development of three Spiegelmer® drug candidates • targeting MCP-1/CCL2 in diabetic nephropathy (Emapticap pegol / NOX-E36) • SDF-1/CXCL12 in hematological and solid tumors (Olaptesed pegol / NOX-A12) and • Hepcidin in anemia of chronic disease (Lexaptepid pegol / NOX-H94)
Dr. med. Matthias Baumann, Chief Medical Officer, NOXXON Pharma AG, Berlin (D)
- 11.00 **RNAi and Tumor Microenvironment: Pre-clinical and Clinical Evidence**
Dr. Amotz Shemi, PhD, CEO, Silenseed LTD, Jerusalem, Israel
- 11.15 **Nanomedicine-induced Oxidation-reduction Potential (ORP) Changes**
Prof. Dr. med. Janos Szebeni, Nanomedicine Research and Education Center, Semmelweis University, Budapest (H)
- 11.30 **Further Questions and Debate**
- 11.40 **Plenary Session in this Hall**

Wednesday, Hall Sydney

- Parallel 2**
Chair **35. Cardiology and Atherosclerosis (12 minutes & 3 minutes for questions)**
Prof. Dr. med. Patrick Hunziker, Deputy Chief of the Intensive Care Clinic, University Hospital Basel (CH)
- 10.15 **Introduction to the State of the Art and Point of Start for Nanomedical Help**
Prof. Dr. med. Patrick Hunziker, Deputy Chief of the Intensive Care Clinic, University Hospital Basel (CH)
- 10.30 **NanoAthero – Results of this FP7-EU-Programme**
Prof. Dr. Didier Letourneur, Director of Cardiovascular Bioengineering, Laboratory for Translational Vascular Science, INSERM, Paris (F)
- 10.45 **CosmoPHOS Initiative against Atherosclerosis in Progress**
Dr. med. Panagiotis N. Trohopoulos, Cardiologist, Founder and Scientific / Exploitation / Strategic Coordinator, EU FP7 NMP Funded CosmoPHOS-nano Project, Founder and Managing Director of the CosmoPHOS Ltd, Thessaloniki (GR)

11.00 **The Role of T-cell / Macrophage Polarization for the Destabilization of Atherosclerotic Lesions**
Prof. Dr. med. Harald Mangge, Clinical Institute for Medical and Chemical Laboratory Diagnosis,
Medical University of Graz (A)

11.15 **The Interplay between Lipids and Inflammation: Opportunities for Targeting?**
Prof. Dr. med. Erik Stroes, Chair Department of Vascular Medicine, Academic Medical Center
(AMC), Amsterdam (NL)

11.30 **Further Questions and Debate**

11.40 **Change to Hall Montreal for keynote lecture**

Wednesday, Hall Singapore

Parallel 3 **36. New Insights into Basic Mechanisms of Cancer (12 min & 3 min Questions)**

Chair **Dr. Silke Krol**, Principal Investigator and Head of Nanomedicine lab, IRCCS, Istituto Oncologico
"Giovanni Paolo II", Bari (I) and Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milano (I)

10.15 **Transcription Factors, miRNAs and lncRNAs Regulating EMT and Cancer Metastasis**
Prof. Dr. Gerhard Christofori, Department of Biomedicine, University of Basel, Basel (CH)

10.30 **Selectivity of Drug Release Rate of Nano-liposome Based Nano-drug: One of the Keys to Determine
Nano-drug Therapeutic Index**

Prof. Dr. Yechezkel (Chezy) Barenholz, Head of Membrane and Liposome Research Lab, Hebrew
University Hadassah Medical School, Jerusalem (IL)

10.45 **Tumor Stroma as a Barrier and Target in Cancer: Novel Models and Targeting Strategies**
Dr. Jai Prakash, PhD, Associate Professor – Targeted Therapeutics, Department of Biomaterials, Science
and Technology, MIRA Institute for Biomedical Technology and Technical Medicine, University of
Twente, Enschede (NL)

11.00 **DiaChemo - PoC Device for Quantification of Chemotherapeutic Drugs**
Dr. Silke Krol, Principal investigator and Head of Nanomedicine lab, IRCCS, Istituto Oncologico
"Giovanni Paolo II", Bari (I) and Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milano (I)

11.15 **Questions and Debate**

11.40 **Change to Hall Montreal for keynote lecture**

Wednesday, Hall Rio

Parallel 4 **37. The European Nanomedicine Characterization Lab infrastructure (EUNCL)**

Chair **Patrick Boisseau**, CEA-Léti, Coordinator Task Force on ESTHER, Chairman of the ETPN, Grenoble (F)

10.15 **Introduction on the European Nanomedicine Characterization Laboratory (EUNCL)**
Patrick Boisseau, CEA-Léti, EUNCL infrastructure coordinator, Chairman of the ETPN, Grenoble (F)

10.25 **How can EUNCL Support Industry**
Dr. Caroline Lemarchand, Pharm D, PhD Preclinical and Pharmaceutical Development Director, Onxeo, Paris (F)

10.35 **EU-US Cooperation on Nano-characterization**
Dr. Jennifer Grossman Senior Scientist, Frederick National Lab for Cancer Research, Frederick (USA)

10.45 **Connecting EUNCL with Regulators**
Dr. Susanne Bremer-Hoffmann, Institute for Health and Consumer Protection (IHCP), European Joint
Research Centre (EC-JRC), Ispra (I)

10.55 **The Next Frontiers in Nano-characterization**
Dr. Sven Even Borgos, Research Scientist at SINTEF Materials and Chemistry, Dept. of Biotechnology and
Nanomedicine, Trondheim (N)

11.05 **How can Stakeholders Access EUNCL?**
Dr. Simon Baconnier, Innovation Project Manager, CEA-Clinathec, Grenoble (F)

11.15 **Questions and Debate**

11.40 **Change to Hall Montreal for Keynote Lecture**

Section 14 : Satellite 4: Ethics in Nanomedicine

Wednesday, Hall Lima (Ground-Floor)

Satellite **38. Ethics in Nanomedicine**

Session established by the European Forum for Good Clinical Practice, (EFGCP), Brussels (B)

Chair **Dr. med. Ingrid Klingmann**, PhD, Chairman, European Forum for Good Clinical Practice (EFGCP)
Wezembeek-Oppem (B)

10.15 **The Patient's Voice**

Dr. med. Ian Banks, European Men's Health Forum, Ballynahinch (UK)

10.35 **The Clinical Researcher's Voice**

Prof. Dr. med. Christoph Alexiou, Ass. Medical Director, Else Kröner-Fresenius-Foundation Professorship, Head Division Experimental Oncology and Nanomedicine, ENT-Clinic, University Clinic, Erlangen (D)

10.55 **The Ethicist's Voice**

Dr. Nicola Stingelin, Independent Research Ethics Advisor; Associate Researcher, University of Basel, Institute for Biomedical Ethics, Basel (CH)

11.15 **Questions and Debate**

11.40 **Change to Hall Montreal for Keynote Lecture**

Section 15: Plenary Session

Wednesday, Hall Montreal

Plenary **39. Curing Instead of Treating Autoimmune Diseases with Nanomedicines**

Chair **Prof. Dr. Gerrit Borchard**, Professor Biopharmaceutical Sciences, President of the Swiss Society of Pharmaceutical Sciences, Vice President of the European Federation of Pharmaceutical Sciences, School of Pharmaceutical Sciences, Universities of Geneva and Lausanne (CH)

Keynote lecture

11.50 **Peptide-major Histocompatibility Complex (pMHC)-based Nanomedicines for the Treatment of Autoimmune Diseases**

Prof. Dr. med. Pere Santamaria, Professor, Department of Microbiology, Immunology and Infectious Diseases, University of Calgary (CA), and Group Leader, Institut D'Investigacions Biomèdiques August Pi i Sunyer (ES)

12.15 **Questions and Debate**

12.30 **Lunch**

Section 16 : 4 Parallel Sessions

Wednesday, Hall Montreal

Parallel 1 **40. Bio-corona and its Relevance for Nanomedicine and Delivery (10 Min & 5 min for Questions)**

Chair **Prof. Dr. Kenneth A. Dawson**, Professor of Physical Chemistry, School of Chemistry & Chemical Biology; Director of the Centre for BioNano Interactions, Dublin (IRL)

13.30 **Biological Identity and Recognition on the Nanoscale**

Prof. Dr. Kenneth A. Dawson, Professor of Physical Chemistry School of Chemistry & Chemical Biology; Director of the Centre for BioNano Interactions, Dublin (IRL)

- 13.45 **The Miracle of PEGylation: Specific Proteins Determine the Stealth Effect of Polyethylene Glycol**
Prof. Dr. med. Volker Mailänder, Leader of the joint research group between the University Clinic Internal Medicine III, Johannes-Gutenberg University Mainz and the Max Planck Institute (MPI) for Polymer Science, Mainz (D)
- 14.00 **Thermosensitivity of Temperature-sensitive Liposomes is Affected by their in Vivo Biomolecular Protein Corona**
Dr. Zahraa S. Al-Ahmady, Nanomedicine Lab, Faculty of Medical & Human Sciences, University of Manchester, Manchester Pharmacy School, Manchester (UK)
- 14.15 **Biological Recognition of Biomolecular Corona**
Dr. Yan Yan, Centre for BioNano Interactions, School of Chemistry and Chemical Biology, University College Dublin (IRL)
- 14.30 **Protein Corona in Vitro as in Vivo?**
Dr. Marijana Mionic Ebersold, Scientific Collaborator, Centre Hospitalier Universitaire Vaudois (CHUV) and Laboratory of Powder Technology (LTP), Ecole Polytechnique Federale de Lausanne (EPFL), Lausanne (CH)
- Questions and Debate after each talk**
- 14.45 **Change to Hall Montreal**
- Wednesday, Hall Sydney
- Parallel 2
Chair **41. Tissue Engineering for Drug Development**
Dr. Markus Rimann, Zurich University of Applied Sciences, Wädenswil (CH)
- 13.30 **3D Tissue Models – New Perspectives for Medicine**
Dr. Markus Rimann, Zurich University of Applied Sciences, Wädenswil (CH)
- 13.40 **Organs-on-chip for Drug Development**
Prof. Dr. Olivier Guenat, ARTORG Center, Medical Faculty, University of Bern, Bern (CH)
- 13.50 **Human Multi-Organ-Chip Technologies – a Step towards Emulation of Systemic Aspects of Human Biology in Vitro**
Dipl. Ing. Christopher Drewell, TissUse GmbH, Berlin (D)
- 14.00 **Stem cell-based Microtissue Engineering for Drug Development**
Dr. Jens Kelm, InSphero, AG, Schlieren (CH)
- 14.10 **Smart and Living Implant Equipped with Active therapeutics and Stem cells for Regenerative NanoMedicine**
Dr. Nadia Benkirane-Jessel, Research Director and Head of the Osteoarticular and Dental Regenerative Nanomedicine Laboratory, FMTS, INSERM UMR 1109, Strasbourg (F)
- 14.20 **Questions and Debate after each talk**
- 14.45 **Change to Hall Montreal**
- Wednesday, Hall Singapore
- Parallel 3
Chair **42. Nanomedicine in Brain Disease (13 min. and 2 min for Questions)**
Prof. Dr. Avi Schroeder, PhD, Assistant Professor of Chemical Engineering Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies Technion - Israel Institute of Technology, Haifa (IL)
- 13.30 **New Strategies with Local Brain-nano-intervention between Nano-science and Neurosciences**
Prof. Dr. med. François Berger, Director of the CLINATEC, Centre De Recherche Biomedical Edmond J. Safra, CEA, Grenoble (F)
- 13.45 **Phase Transitions in Biology: A Novel Way to Think about Neurodegeneration**
Dr. Avinash Patel, Post-Doctoral, Fellow Hyman Laboratory, Max Planck Institute, Dresden (D)

- 14.00 **The Brain Shuttle: Delivering Biologics across the BBB**
Dr. Alain C. Tissot, Head, Immune Biology, Large Molecule Research, Roche Pharma Research & Early Development, Roche Innovation Center, Penzberg (D)
- 14.15 **A New Nano Workbench to Study and Control the Formation of Oligo-fibrils Made by Alfa-Synuclein in Parkinson's disease**
Prof. Dr. Giacinto Scoles, Department of Medical and Biological Sciences, University Hospital, University of Udine, Udine (I) and Biology Department, Temple University, Philadelphia, PA (USA)
- 14.30 **Further Questions and Debate**
- 14.45 **Change to Hall Montreal**
- Wednesday, Hall Rio
- Parallel 4 **43. Medical Applications for Nanomedicine in Oncology**
Chair **Dr. Marieluise Wippermann**, CEO, TecoMedical Ltd, Sissach (CH)
- 13.30 **Radionanomedicine: Exogenous and Endogenous**
Prof. Dong Soo Lee MD, PhD, Dept. of Nuclear Medicine, College of Medicine, National University Seoul, Seoul (ROK)
- 13.40 **A Bacterial Platform for Targeted Delivery of Proteins into Cancer Cells**
Dr. Simon Ittig, Project Manager, Biozentrum, University of Basel, Basel (CH)
- 13.50 **Filled and Functionalized Radioactive Nanocapsules towards Targeted Radiotherapy in Vivo**
Dr. Julie Tzu-Wen Wang, Institute of Pharmaceutical Science, King's College London (UK)
- 14.00 **Targeting Strategies for the Detection of Prostate Cancer Metastases to Lymph Nodes**
Dr. Olivier Jordan, Senior lecturer, School of pharmaceutical sciences, University of Geneva (CH)
- 14.10 **Questions and Debate**
- 14.45 **Change to Hall Montreal**

Section 17 : Satellite 5: Education and Workforce Training in Nanomedicine

- Wednesday, Hall Lima (Ground-Floor)
- Satellite **44. Clarifying Education and Workforce Training - Needs in Nanomedicine and Targeted Drug Delivery (15 min & 5 min for Questions)**
Chair **Dr. Anil Patri**, Chair, Nanotechnology Task Force, Director, NCTR-ORA Nanotechnology Core Facility, U.S. Food and Drug Administration, National Center for Toxicological Research (NCTR), Jefferson, Arkansas USA,

Today's fast changing technological environment with rapidly emerging scientific fields (including nanotechnology) requires a more dynamic and responsive educational ecosystem with seamless links through high school, higher education and research centers to achieve optimal performance. Proper synchronization of the educational system with emerging technologies and the needs of modern industry is very important but likely not to be sufficient in its own right. An equally important outcome of the integrated ecosystem should be a suite of products designed to facilitate improvements in life quality and/or expectancy. It is extremely important to establish efficient and simple regulatory systems to shorten the time to market, while ensuring the safety of new products. Education and training are central factors in shortening regulatory procedures and these issues will be discussed in this session.

- 13.30 **Nanomedicine: A Clinical Pharmacologists view of Nanomedicine Regulation**
Prof. Dr. Andrew Owen, BSc, MSc, PhD, FSB, Professor for Molecular and Clinical Pharmacology, University of Liverpool, Liverpool (UK)
- 13.50 **EduNano: Education, training and cutting edge knowledge sharing on Nano Technologies from high school through Higher Education and on to Industry**
Jack Barokas, EduNano Tempus project local coordinator at Tel Aviv University, Tel Aviv (IL)

14.10 **Regulatory Science Core Competencies to Guide Education and Training Pathways**
Dr. Scott Steele, Ph.D., Director, Government and Academic Research Alliances, Associate Professor,
Public Health Sciences University of Rochester (USA)

14.30 **Further Questions and Debate**

14.45 **Short Break and Change to Hall Montreal**

Section 18: Plenary Session

Wednesday, Hall Montreal

Plenary
Chair

45. Toward the Success to Translate Nanomedicine from Finding to Patient

Dr. med. h.c. Beat Löffler, MA, CEO of the CLINAM-Foundation, Basel (CH)

Prof. Dr. med. Patrick Hunziker, President of the International Society for Nanomedicine, Basel (CH)

Two Experts in Nanomedicine and Targeted Medicine show on how Nanoparticle Design, Development and Novel Pathways for the Design of Efficient Anticancer Immunotherapies will lead to the Advancement of Nanomedicine and Targeted Medicine to the Benefit of Patient.

Prof. Omid Farokhzad, MD is an Associate Professor at Harvard Medical School (HMS) and a physician-scientist in the Department of Anesthesiology at Brigham and Women's Hospital (BWH). He directs the Laboratory of Nanomedicine and Biomaterials at BWH. He is a faculty member of the Brigham Research Institute Cancer Research Center. He is a member of the Dana Farber/Harvard Cancer Center Programs in Prostate Cancer and Cancer Cell Biology. His research is focused on the development of therapeutic nanoparticle technologies; most notably, he pioneered the high throughput combinatorial development and screening of multifunctional nanoparticles for medical applications. The technologies that Dr. Farokhzad has developed with collaborators at HMS and MIT formed the basis for the launch of four biotechnology companies: BIND Therapeutics where he served on its Board of Directors from 2006 until 2014; and Selecta Biosciences, Tarveda Therapeutics (formerly Blend Therapeutics), and Koan Biotherapeutics, where he currently serves on their Board of Directors. These companies are translating the aforementioned academic innovations toward commercialization and societal impact.

Keynote lecture

15.00 **Tumor Microenvironment Variability and Implications for New Nanoparticle Design and Patient Selection**

Prof. Dr. med. Omid Farokhzad, Associate Professor and Director of Laboratory of

Nanomedicine and Biomaterials, Harvard Medical School and Brigham and Women's Hospital, Boston (USA)

15.25 **Questions and Debate**

Prof. Dr. Jérôme Galon is Director of Research at INSERM (French NIH) expert in the fields of immunology and cancer, and head of the laboratory of Integrative Cancer Immunology, in Paris, France. His work on the comprehensive analysis of the tumor-microenvironment and the role of T-cells in human cancer led to the demonstration of the importance of adaptive pre-existing immunity in human cancer, and the concept of cancer immune-contexture. He pioneered the Immunoscore. He is the co-founder of HaliDx Company. HaliDx designs and develops diagnostic tests in oncology utilizing the immune contexture of cancers. HaliDx ambition is to change the paradigm of cancer diagnosis, by integrating cutting edge monitoring of immune parameters in cancer. An innovative start-up with strong leadership and expertise in cancer diagnostics, HaliDx has an experienced team of 80 employees and compliant facilities to develop, manufacture, deliver and market in vitro diagnostic products and services in Immuno-Oncology.

Keynote lecture

15.40 **Redefining Cancer by Integrating the Immune System: Transferring Cutting Edge Medicine to the Patients**

Prof. Dr. Jérôme Galon, Director of Research, French National Institute of the Health and Medical Research (INSERM), Chief, laboratory of Integrative Cancer Immunology, Cordeliers Research Center, Co-Founder of HaliDx Company, Paris (F)

16.05 **Questions and Debate**

Section 19: Plenary Session

- Plenary Chair **46. The Spur on Nanomedicine – Voices from the participants of CLINAM 9/16**
Prof. Dr. Yechezkel (Chezy) Barenholz, Head of Membrane and Liposome Research Lab, Hebrew University Hadassah Medical School, Jerusalem (IL)
- 16.20 **Debate and one minute Statements**
After 190 interventions the floor is open to the Plenum for “Short Statements”
- 16.50 **Closing words on the CLINAM 9 /2016 Debate Conference**
Prof. Dr. med. Patrick Hunziker, President of the International Society for Nanomedicine, Basel (CH)
- 17.00 **End of CLINAM 9 / 2016**
- CLINAM 10 / 2017 will be held in Basel from May 7 - May 11, 2017**
- 18.30 **Light Farewell Dinner for staying speakers and invited Guests**

INVITATION FOR SHAPING CLINAM 2017

CLINAM in its 10th Edition will besides the programme consist of many Satellite Meetings. The CLINAM Foundation encourages all stakeholders in cutting edge medicine related to Nanomedicine and Targeted Medicine and Personalized Medicine to contact us as early as possible, if there is an interest to collaborate for May 2017 and to become an active partner of the worldwide CLINAM-network.

General Information

Organizers Office

Please contact the CLINAM for more information
European Foundation for Clinical Nanomedicine
Alemannengasse 12, CH-4016 Basel, Switzerland
Phone + 41 61 695 93 95 Fax +41 61 695 93 90
E-Mail clinam@clinam.org Website www.clinam.org

For registration-matters, please contact
Organizers Schweiz GmbH, CLINAM SUMMIT 9/2016
Obere Egg 2, CH 4312 Magden, Switzerland
Phone +41 61 836 98 78 E-Mail registration@organizers.ch
Website www.organizers.ch

Copyrights and Liability by CLINAM

This programme is owned in its contents and concept by the European Foundation for Clinical Nanomedicine, CLINAM, Basel, Switzerland. The copyright of the speeches belongs to the speakers. The entire programme is subject to possible changes. For the conference Center CLINAM has a legal liability insurance for the days of the meeting. This does not include any other areas beyond the center. Insurance of goods is matter of the Exhibitors.

The Exhibitors 2016 and their Target Group

The Exhibitors meet their target visitors on 1 single spot at CLINAM 9 / 2016. The Summit becomes the place for the pulse of the market and early sales in the field of cutting-edge medicine. Universities from 7 countries are showing results of their research also related to the whole country.

Live Testing the STED Microscope

The presence of a STED Microscope will give for participants of CLINAM the possibility to bring samples and to investigate the revolutionary visibility. All participants get a link for label protocols before the Summit which gives information how to prepare the samples. STED Microscopes are currently in the market by the companies Abberior and Leica.

The initiative to enable people to investigate comes from CLINAM in cooperation with Beckman Coulter, Leica and Abberior.

Exhibitors 2016



EVA - The Basel Start-up Agency, Basel, Switzerland
www.eva-basel.ch



Lipoid AG, Steinhausen, Switzerland
www.lipoid.com



TECOmedical AG, Sissach, Switzerland
www.tecomedical.com



NUOMEDIS AG, Liestal, Switzerland
www.nuomedis.com



Particle Metrix GmbH, Meerbusch, Germany
www.particle-metrix.eu



Izon Science Europe Ltd., Oxford, United Kingdom
www.izon.com



Beckmann Coulter GmbH,
Krefeld, Germany
www.beckmancoulter.com



Malvern Instruments Ltd., Malvern, Wiltshire, United Kingdom
www.malvern.com



Polymun Scientific, Klosterneuburg, Austria
www.polymun.at



Seroscience Ltd., Budapest, Hungary
www.seroscience.com



InnoMedica AG, Bern, Switzerland
www.innomedica.com



De Gruyter, Berlin, Germany
www.degruyter.com



i-Net Innovation Networks, Basel, Switzerland
www.i-net.ch

University Village and Small Speeches

The University Village is the space for universities and research institutes, giving them opportunity to present novel Approaches, new research projects and initial outcomes of research and experimental results as well as first patents. Researchers and engineers can use the foyer to show the existing tools, instruments and materials in the field of regenerative medicine, diagnostics, targeted drug delivery systems, novel materials for nanoparticles, imaging, biomaterials / biosensors / biomarkers, Nanomedicine-related medical tools and medical instrumentation as well as existing nanobased clinical medications.

Small Speeches

Poster presenters and University Village members are eligible for presentations in a special session of Small Speeches, 3 minutes in length and serving to highlight the research activities in Nanotechnology and Targeted Medicine. They must comprise three slides, • Slide 1: general introduction to the topic • Slide 2: some of the highlights of submitters' work and institutions' work • Slide 3: the proof as to how the work fits into the area of Nanomedicine including a glimpse into the future. Application for Small Speeches Sessions is possible any time after acceptance of your poster in writing to the organizers. The competition to get a slot is quit high.

Exhibiting Universities in 2016

- Switzerland (Basel) • Denmark (Copenhagen) • Israel (Tel Aviv)
- England (Durham University) • The Netherlands (Twente)
- Hungary (Budapest) • Norway (Trondheim)

Late Submission of Posters (not included in Proceedings)

Posters can still be accepted until June 23 but the abstracts will not be in the Proceedings and handouts have to be brought by the presenters to Basel

CLINAM invites on interdisciplinary level members in the field of Clinic, Engineering, Industry, Venture, all related Science Faculties, young members from universities and academies and highly skilled youngsters, political decision makers that work in the field and members of regulatory authorities to submit abstracts for papers and posters, They must cover original research aimed at future or current applications of nanoscience and targeted medicine including clinical trial designs, reports of ongoing and processes, eye and ear disease, tuberculosis, HIV, Ebola, tissue repair, orthopedics, ...etc. • **Technology:** Nanosystems, nanoparticles, nanoanalytics and diagnostics, toxicology, nano-imaging, targeted drug delivery using nanoparticles, GMP and quality assurance, propositions for solving a medical problem in a novel way by the use of nanotechnology, novel concepts and ideas if they can be supported by thorough reasoning and could lead to novel research and solutions, materials for use in nanotechnology and targeted medicine, concepts, diagnosis and therapy in the field of personalized medicine: clinical diagnosis and management on the individual patient's clinical signs and symptoms, medical and family history, and data from laboratory and imaging evaluation to diagnose and treat illnesses, genetic testing leading to more personalized treatments. Also relevant novel tools for translational research and diagnostics are of high interest, etc.... • **Implications:** Implications of Nanomedicine for society, developing countries, environment, risks and benefits, public health finance, health economics, and other subjects, etc. • **Strategy, Government and Politics:** Strategy building and policy processes in Nanomedicine. Strategic approaches towards establishing a unified funding area for nanotechnologies for medical research. Policy processes to foster leadership in Nanomedicine, regulatory authority topics as well as financial and marketing matters etc. • **Industry:** Industry projects and solutions in Nanomedicine and targeted medicine, tools related to Nanomedicine and targeted medicine. Industry models for the Future large-scale production, Good Manufacturing Practice, etc. • **Exhibitors:** Integrated interventions of exhibitors of scientific or technical relevance and do not have the solely the purpose of promoting the trademark.

Sending Paper Abstract / Poster Abstract, Procedure

• **All correspondence regarding Submission** of Posters has to be sent to: submit2016@clinam.org • abstract of poster abstract, (*Microsoft Word, RTF, or Open document file format, using Times New Roman, font size 11, single spacing NO PDF*). The submission must not be longer than three pages, including metadata and figures (one figure is obligatory). All illustrations, must be placed within the text at the appropriate points.) *For control purposes you may send in addition for above text a pdf*. Index your file as follows: **Last name.First name_Submission16.xx** (xx = docx, or rtf, doc or word 13 document). • **CV** Add a short **narrative** CV (1 page maximum) and index as follows: **Last name.First name_CV16.xx** • **Portrait Photo** Send us a head picture (*in gif or jpg 600 dpi and not word copy paste!*) Index your file as follows: **Last name.First name_Picture16.x**

Decision for Acceptance

Decision for Acceptance or Declination **will be given soon after submission**. You will receive a Decision Form, which announces eligibility or declination. In the case of acceptance you have to register according to your category **within 24 hours after receipt**

Installation of Posters, Size and Presentation Times

Posters will be located in the Foyer visible for all conference attendees. The meeting breaks and lunches will be the preferred time to study the posters. During lunch and breaks, the authors are asked to be present close to their poster. Posters are to be presented in the **size of 1.40 meter high and 1.00 meter wide**. There will be the CLINAM-Poster Prize. **Poster installation is on June 27 as from 06.30 until 8.00 h latest and the posters can be removed on June 29, as from 17.00 until latest 17.45**. The Poster Prizes will be handed out Tuesday during the Aperitif.

Special Event of the FP7 Project “NanoAthero” on Sunday June 26, 2016

A special workshop to the topic of Atherosclerosis at the CLINAM Summit targets youngsters of members of NanoAthero involved institutions. (Students and up to 5 years of Postdoc experience). They have the opportunity to attend on **Sunday, June 26 from 14.30 h to 17.00 h** in Basel an Atherosclerosis Session. **An experienced member of NanoAthero will give an introduction** and after that there will be a 2.5 hours debate. **After this all participants will have Dinner together.** Those participating in this meeting will have free access for the Monday of the CLINAM-Summit. The NanoAthero- Dissemination will cover 2 nights of Hotel**/** for those profiting of this. Those who want to stay for the whole conference will have to register with additional at rate of additional 350.-- €. **Interested members write to CLINAM and will receive a special “voucher” which has to be filled in when registering.** The meeting will be held in room Osaka (Congress Center Basel)

Facilitators of the European Summit for Clinical Nanomedicine 2018

The European Foundation for Clinical Nanomedicine is very grateful that this Summit becomes possible every year due to the great financial support of the State of Switzerland, the Canton of Basel-Stadt and Basel-Land, institutions, industry and private donators. They all do not take any influence on the programme and respect that CLINAM is a strictly neutral non for profit platform. All these Sponsors believe that the best development for novel technology and novel applications profits enormously by having regularly a worldwide community meeting. This creates cooperation, trust and leads to quantum leaps in the development, which are only possible when people with knowledge and expertise strive *together* towards their common goal. The CLINAM-Foundation Staff does everything they can, to respond in best way to the confidence that they receive and shape a challenging programme.

Registration Fees for the CLINAM Exhibition 9 /2016

Category Currency is EURO	Regular	Fellowship 1 until 1.6.2016	Fellowship 2 until 1.6.2016	1 Day regular	Reductions for groups of participants	
Academy	790.00	570.00	490.00	280.00	3 Pers	- 10 %
Government	1'100.00	780.00	700.00	380.00	4 "	- 12 %
Industry	1'600.00	1'200.00	1000.00	500.00	5 "	- 15 %
Exhibitors	850.00		600.00	350.00	6 <	- 20 %
Students	500.00	350.00	300.00	200.00	No reductions for Fellowship Groups	
Paper/Poster Submitters	Special rate of 610.00 €; (academy) and 390.00€ (students)					
Your contribution to the Brokerage Dinner on Monday, June 27, 2016. 8.00 pm is 50. 00 € extra, not included in the Registration Fee.						
Members of the European Society for Nanomedicine benefit from a 5% reduction in all categories (www.esnam.org) Cannot be cumulated to other reductions						
ALL PAYMENTS HAVE TO BE MADE BY CREDIT CARD ON A SECURE PAGE. THE PAYMENT OF BILL BY BANK ACCOUNT IS SUBJECT TO ADDITIONAL CHARGES OF 10 EURO.						

Registration Fees for the CLINAM Summit 9 /2016

Lump sum Package for 4 m2 including Registration = 3'500.00 € Lump sum Package for Start-ups incl. Registration = 2'800.00 €

Exhibition Space

4 m ²	2'500.00 €
6 m ²	3'750.00 €
8 m ²	5'000.00 €
Company plate A3 with Logo and name	INCLUDED
1 table, 2 chairs, power connection wireless	150.00 €
Exhibitor Resistration	850.00 €

Booth Construction if needed is separate


4 m ²	680.00 €
6 m ²	1'020.00 €
8 m ²	1'360.00 €
Space beyond	150.00 € per m ²

Construction: 2 walls, 1 table, 2 chairs, power connection, wireless lan

ALL PAYMENTS HAVE TO BE MADE BY CREDIT CARD ON A SECURE PAGE. THE PAYMENT OF BILL BY BANK ACCOUNT IS SUBJECT TO ADDITIONAL CHARGES OF 10 EURO.

How to get to Basel Congress Center

Coming by train: You will arrive at the Swiss Train Station (SBB). From there you take Tram number 2. You will after 5 stations within 10 minutes be at the conference center. The station is called “Messeplatz” and is announced. Coming from the German Station it is only 2 stops, also with tram number 2 (or also 6) in opposite direction. The costs for a cab from SBB are about 17.-- CHF. **Coming by flight to Basel-Mulhouse-Freiburg Airport:** This is a 15 minutes’ drive to the Congress Center Basel. There is an easy connection from Euro-Airport to the exhibition center in downtown Basel by public transport (Bus Nr. 50), via the central Swiss railway station (Bahnhof SBB). From Bahnhof SBB the tram line no. 2 (see above) serves Basel Exhibition square directly. The costs for a cab are about 40.-- CHF **Coming from Zurich Airport:** There are frequent trains between Basel SBB station and Zurich Airport taking less than an hour. You arrive in Basel at the Swiss Train Station and take as described above the tram number 2 or a cab.



CLINAM 9 /2016 European & Global Summit for Cutting Edge Medicine

Clinical Nanomedicine and Targeted Medicine

Basel, Switzerland, June 26 – 29, 2016

Primary Sponsors



Schweizerische Eidgenossenschaft
Confédération suisse
Confederazione Svizzera
Confederaziun svizra

State Secretariat for Education,
Research and Innovation SERI

CLARIANT

isaac
dreyfus
bernheim
FONDATION/STIFTUNG

Further Sponsors



TECOmedical Group
always your partner

Lonza



GAGAG



TARVEDA
THERAPEUTICS

Basel+

Löffler & Associates
Concept Engineering



FNSNF
FONDS NATIONAL SUISSE
SCHWEIZERISCHER NATIONALFONDS
FONDO NAZIONALE SVIZZERO
SWISS NATIONAL SCIENCE FOUNDATION



BASEL
LANDSCHAFT

